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resistance, increase the risk of cardiovascular disease 13-16
As atherosclerosis increases with age, HIV-patients on chronic treatment will 
have the same risks as HIV-uninfected patients. Since HIV itself and ART also
increase this risk, the overall rise of cardiovascular diseases is much higher than 
in the normal population. Dyslipidaemia to levels associated with increased
cardiovascular disease occur in even up to 70% of HIV-infected patients 
receiving ART. The prevalence of lipodystrophy varies widely and has been 
estimated at 7-84% among adult patients and depends on the criteria to define
this syndrome. The HIV Lipodystrophy Case Definition Study Group evaluated 
a model to diagnose lipodystrophy; including a score system for age, sex, 
duration of HIV-infection, HIV-disease stage, waist:hip ratio, anion gap, serum
HDL-cholesterol concentration, trunk:peripheral fat ratio, percentage of leg fat
and intra-abdominal:extra-abdominal fat ratio. Application of this score 
resulted in a sensitivity of 79% and a specificity of 80% 17. 
Toxicity is a major problem since it does affect compliance and resistance. 
Patients experiencing side effects find it difficult being motivated to continue
their medication. They might interrupt their treatment which might induce 
resistance of the virus. In case of serious side effects their physicians will decide
to stop ART and change to a better tolerated regimen if possible. In some cases
the addition of another drug can solve the problem, for instance lipid lowering
drugs in hyperlipidaemia of loperamide in case of diarrhoea.
The following factors play a role in the development of toxicity: pharmaco-dynamic
and kinetic parameters of the drugs and genetic parameters of the patients.
Mitochondrial impairment seen in NRTI use is due to a specific pharmaco-dynamic
effect of this class of drugs. Selected side effects for NRTIs are neuropathy, myopathy,
pancreatitis, anaemia, hepatitis and lactic acidosis. The origin of these adverse
events lies partly in the potential of NRTIs to interfere with DNA polymerase γ, 
an enzyme essential for mitochondrial DNA (mtDNA) strands, resulting in impaired
mitochondrial function. In this way NRTI incorporation leads to chain termination.
However, the mechanism for mitochondrial toxicity includes also direct inhibition
of mtDNA polymerase γ without chain termination, persistence of the incorporated
analogues in mtDNA because of inefficient excision resulting in a defective mtDNA
template, or combination of these mechanisms. This so-called mitochondrial 
toxicity is a specific effect of NRTIs as a class. It should be noted that some side
effects, which occur by example in stavudine, do not occur in other NRTIs 18.
Kinetic parameters play a role in side effects when toxicity is related to plasma
concentrations of drugs. Especially the PI group has been known for its wide
inter-subject and intra-subject variation resulting in a wide variability of plasma
concentrations. Therefore, therapeutic drug monitoring is advised in these drugs
both for prevention of drug levels below the therapeutic range as for prevention
of toxic drug levels 19. Previous studies have demonstrated a relationship between
drug exposure and efficacy and toxicity. Nowadays, measurement of plasma drug
concentrations is applied for non nucleoside reverse transcriptase inhibitors
(NNRTIs) and PIs. It is frequently stated that plasma NRTI levels do not correlate
12
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Despite the progress in the insight of HIV-infection itself and the development
of a series of drugs to suppress replication of the humane immunodeficiency
virus (HIV), HIV-infection remains a challenging therapeutic problem. 
Highly active antiretroviral therapy (HAART) consists of a combination of at least
three drugs from two different classes of antiretroviral drugs 1. By this approach
HIV-replication can be suppressed for long time and HIV-infection has turned into
a more chronic disease. However, the other side of the picture is the occurrence of
serious adverse effects, which is an important problem for physicians treating
HIV-patients.
Antiretroviral therapy (ART) has been associated with considerable adverse events
(AEs). Incidences vary, but laboratory adverse events have been reported in up to
25% and clinical AEs in even up to 45% of patients 2-4. One cohort with a median
follow up of 6 years showed that during this period laboratory adverse events
were associated with a significant higher mortality 5. In contrast, for clinical AEs
no significant association with increased mortality was found. Physicians seem 
to change treatments to relieve clinical symptoms, while accepting laboratory AEs.
However, in this cohort the burden of laboratory AEs to antiretroviral drugs was
associated with a higher mortality. In 2007 the monitoring of HIV-infection in 
the Netherlands showed that older age and lower weight at the start of ART were
associated with a shorter time to develop toxicity 6. Most frequently reported side
effects in this report were nausea (18%), anaemia (12%), rash (10%), diarrhoea
(10%) and vomiting (10%).
Adverse events seen shortly after the initiation of ART are gastrointestinal 
problems, such as nausea, vomiting and diarrhoea, which can be seen in all 
ART drug classes, although diarrhoea has been mainly associated with protease
inhibitor (PI) use. Furthermore, hypersensitivity reactions with rash and fever are
seen. This is especially known from amprenavir, abacavir and nevirapine, with
incidence rates of 28%, 7-16% and 5% respectively 3;7. It is an important side
effect since fatal events have been reported with rechallenge of abacavir. If rash
occurs medication has to be discontinued. 
There are several important long term side effects which might hamper continuation
of ART. The first is mitochondrial impairment seen in nucleoside reverse transcriptase
inhibitor (NRTI) use. The second problem is the risk of cardiovascular disease due
to metabolic complications of protease inhibitors 8;9. These metabolic changes
with lipid alterations and impaired glucose tolerance with insulin resistance 
can be seen with or without the so-called lipodystrophy syndrome 10;11.
Hyperglycaemia due to frank diabetes is only seen in a small proportion of
patients (1-6%) 2. This lipodystrophy syndrome or best described as lipohypertrophy/
lipoatrophy syndrome is a demanding problem in HIV-treatment. The lipohyper-
trophy is mainly attributed to PI use, while the lipoatrophy is mainly attributed 
to NRTI use; especially stavudine 12. This syndrome consists of body shape changes
with peripheral fat wasting and central fat accumulation. This syndrome is well
known among patients and feared for its stigmatising appearance. Dyslipidaemia
with hypertriglyceridaemia, decreased high density lipoprotein (HDL) and
increased low density lipoprotein (LDL) and total cholesterol together with insulin
11
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with the intracellular active NRTI-triphosphate metabolite and should therefore
not be used. 
Finally, genetic factors are of great significance in the occurrence of side effects.
Genetic constitution is known to make patients more prone for adverse events.
One example is the hypersensitivity reaction with (severe) rash in nevirapine and
abacavir. For abacavir it has been revealed that there is a relationship between
presence of the HLA B5701 allele and hypersensitivity reactions. Currently it is 
even recommended to test for this HLA type before initiating abacavir therapy.
Furthermore, the HLA-DRB101 allele plays an important role in susceptibility to
cutaneous reactions associated with nevirapine and efavirenz 20-22. 
Diagnosis and early recognition of adverse events is of great importance to 
protect patients from additional medical problems and avoid serious or even 
fatal complications. 
The aim of this thesis is to consider clinical aspects of toxicity in ART by investigating
correlations between patient’s blood chemistry (laboratory values), plasma drug
concentrations and side effects. The thesis focuses on adverse events related to
NRTI-induced mitochondrial toxicity, the stavudine-related lipoatrophy syndrome,
and the PI-associated metabolic syndrome with lipid alterations and impaired
glucose tolerance. 
Section 1 
In chapter 1 we present an overview of adverse events in antiretroviral therapy
focusing on metabolic complications and mitochondrial toxicity, its underlying
mechanisms and possible therapeutic interventions. 
Dyslipidaemia in HIV is revealed to be multifactorial. Factors that play a role in
affecting lipid levels include HIV-infection itself, treatment with antiretrovirals
(especially PIs and stavudine), the effect of changes in body composition and 
possible genetic predisposition to dyslipidaemia. These atherogenic effects 
have their basis on molecular level, were NRTIs interfere with mitochondrial 
RNA transcription leading to mitochondrial DNA depletion and PIs interfere with
cellular transcription factors such as SREBP-1c (sterol regulatory element binding
protein 1c) essential in adipose tissue function. 
Section 2 
In this section laboratory parameters to detect mitochondrial toxicity are studied. 
The initial interest in the subject of this thesis developed after experience with a
fatal case of lactic acidosis in our own hospital, which was due to a serious side
effect of stavudine. Our curiosity for the incidence and mechanism further
increased after collecting more of these cases, which are presented in chapter 2.
The use of the NRTI stavudine was recognised as risk factor for this fatal lactic 
acidosis. We addressed the question to what extent hyperlactataemia plays a role
in the development of adverse events. Lactate levels were collected in a series 
of patients of our outpatient department. Serum lactate and pyruvate levels 
were compared between different groups consisting of HIV-patients with mito-
chondrial toxicity, HIV-patients on antiretroviral therapy without toxic effects, 
HIV-patients without antiretroviral treatment and in healthy volunteers. 
13
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The analysis is outlined in chapter 3. 
In paediatric medicine application of an oral glucose loading test (OGTT) had proven
to be useful to diagnose patients with occult hyperlactataemia due to mitochondrial
disorders. We wondered whether this method would be useful in daily clinical
practice for detection of toxicity in HIV-treated patients. Therefore, an OGTT with
measurement of serum lactates was performed in patients on NRTI therapy with
and without NRTl-related mitochondrial toxicity. The predictive value of an OGTT
for detection of NRTI-related mitochondrial toxicity is evaluated in chapter 4.
Section 3
In this section special attention is paid to serum lipids and glucose alterations
after initiation of ART with a PI. PIs are known to interfere with lipid and 
glucose metabolism resulting in insulin resistance with hyperglycaemia, 
hypertriglyceridaemia, elevated total and LDL-cholesterol and often reduced 
HDL-cholesterol concentrations. Even after short-term therapy with antiretroviral
drugs, these metabolic changes have been observed. 
In chapter 5, we explore whether antiretroviral drugs influence glucose- and
lipid- metabolism in therapy-naive HIV-infected patients. We investigated serum
lipid parameters, glucose, insulin, highly sensitive C-reactive protein and leptin
concentrations during 72 weeks of antiretroviral therapy. Data were collected
within the so called FREE study: a randomised, open label, multicentre strategic
study to evaluate the efficacy and toxicity of an early switch from a PI-containing
regimen (ritonavir boosted lopinavir) to trizivir® (combination drug of zidovudine,
lamivudine and abacavir) on guidance of viral load in HIV-1 infected, antiretroviral
therapy-naive adults. 
Section 4
This section looks at pharmacokinetics more closely and investigated if adverse
events are related to drug exposure and thereby plasma drug concentrations. 
Since lipoatrophy has been associated with stavudine use, we wanted to test the
hypothesis that patients with lipoatrophy are the ones with the highest stavudine
plasma levels. In chapter 6 stavudine plasma concentrations are analysed in
patients with and without lipoatrophy on a stavudine containing regimen for at
least 12 months. 
In literature few data are available describing the influence of PI plasma concen-
trations on lipid changes. Studies in HIV-patients on antiretroviral therapy have
elucidated that there is a wide inter-patient variability when measuring drug
exposure to a standard dose of lopinavir. Lopinavir is known to cause hyper-
lipidaemia. Grade 3 hypercholesterolaemia and hypertriglyceridaemia have even
been reported in 10% and up to 40% of antiretroviral therapy-naive and previous
PI-experienced patients respectively. In chapter 7 plasma lipids and lopinavir
plasma concentrations were measured in a prospective study (FREE study), treating
therapy-naive patients initially with ritonavir boosted lopinavir. By correlating
lipid levels with lopinavir plasma concentrations we wanted to investigate if
higher plasma drug concentrations are related to higher plasma lipid levels. 
In the general discussion and summary the results of the above studies and
future perspectives are provided. 
14
Outline of the thesis
proefschrift def  10-11-2008  13:52  Pagina 14
References
1 Yeni PG, Hammer SM, Hirsch MS, Saag MS, Schechter M, Carpenter CC, Fischl MA, 
Gatell JM, Gazzard BG, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, 
Schooley RT, Thompson MA, Vella S, Volberding PA. Treatment for adult HIV-infection:
2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004; 
292:251-65.
2 Aberg JA, Gallant JE, Anderson J, Oleske JM, Libman H, Currier JS, Stone VE, Kaplan JE.
Primary care guidelines for the management of persons infected with human immuno-
deficiency virus: recommendations of the HIV Medicine Association of the Infectious
Diseases Society of America. Clin Infect Dis 2004; 39:609-29.
3 Montessori V, Press N, Harris M, Akagi L, Montaner JS. Adverse effects of antiretroviral
therapy for HIV-infection. CMAJ 2004; 170:229-38.
4 Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356:1423-30.
5 Keiser O, Fellay J, Opravil M, Hirsch HH, Hirschel B, Bernasconi E, Vernazza PL, 
Rickenbach M, Telenti A, Furrer H. Adverse events to antiretrovirals in the Swiss HIV
Cohort Study: effect on mortality and treatment modification. Antivir Ther 2007; 12:1157-64.
6 Annual report HIV monitoring foundation Academic Hospital Medical Center University
of Amsterdam 2007.
7 Adkins JC, Faulds D. Amprenavir. Drugs 1998; 55:837-42.
8 d’Amati G, di Gioia CR, Gallo P. Pathological findings of HIV-associated cardiovascular
disease. Ann N Y Acad Sci 2001; 946:23-45.
9 Periard D, Cavassini M, Taffe P, Chevalley M, Senn L, Chapuis-Taillard C, de VS, Hayoz D,
Tarr PE. High prevalence of peripheral arterial disease in HIV-infected persons. 
Clin Infect Dis 2008; 46:761-67.
10 Wohl DA, McComsey G, Tebas P, Brown TT, Glesby MJ, Reeds D, Shikuma C, Mulligan K,
Dube M, Wininger D, Huang J, Revuelta M, Currier J, Swindells S, Fichtenbaum C, Basar
M, Tungsiripat M, Meyer W, Weihe J, Wanke C. Current concepts in the diagnosis and
management of metabolic complications of HIV-infection and its therapy. Clin Infect
Dis 2006; 43:645-53.
11 Mallon PW. Pathogenesis of lipodystrophy and lipid abnormalities in patients taking
antiretroviral therapy. AIDS Rev 2007; 9:3-15.
12 Milinkovic A, Martinez E. Current perspectives on HIV-associated lipodystrophy
syndrome. J Antimicrob Chemother 2005; 56:6-9.
13 Calza L, Manfredi R, Pocaterra D, Chiodo F. Risk of premature atherosclerosis and
ischemic heart disease associated with HIV-infection and antiretroviral therapy. 
J Infect 2008; 57:16-32.
14 Oh J, Hegele RA. HIV-associated dyslipidaemia: pathogenesis and treatment. 
Lancet Infect Dis 2007; 7:787-96.
15 Samaras K. Metabolic consequences and therapeutic options in highly active 
antiretroviral therapy in human immunodeficiency virus-1 infection. J Antimicrob
Chemother 2008; 61:238-45.
16 Carpentier A, Patterson BW, Uffelman KD, Salit I, Lewis GF. Mechanism of highly
active antiretroviral therapy-induced hyperlipidemia in HIV-infected individuals.
Atherosclerosis 2005; 178:165-72.
17 Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG. An objective case definition
of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003; 361:726-35.
15
proefschrift def  10-11-2008  13:52  Pagina 15
18 Kohler JJ, Lewis W. A brief overview of mechanisms of mitochondrial toxicity from NRTIs.
Environ Mol Mutagen 2007; 48:166-72.
19 Burger DM, Aarnoutse RE, Hugen PW. Pros and cons of therapeutic drug monitoring 
of antiretroviral agents. Curr Opin Infect Dis 2002; 15:17-22.
20 Vitezica ZG, Milpied B, Lonjou C, Borot N, Ledger TN, Lefebvre A, Hovnanian A. 
HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and
efavirenz. AIDS 2008; 22:540-541.
21 Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jagel-Guedes E, Rugina
S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D,
Benbow A. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;
358:568-79.
22 Stekler J, Maenza J, Stevens C, Holte S, Malhotra U, McElrath MJ, Corey L, Collier AC.
Abacavir hypersensitivity reaction in primary HIV-infection. AIDS 2006; 20:1269-74.
16
Outline of the thesis




proefschrift def  10-11-2008  13:52  Pagina 17
18
Section General introduction
proefschrift def  10-11-2008  13:52  Pagina 18
Chapter 1
Antiretroviral therapy in HIV-patients: 
Aspects of metabolic and mitochondrial toxicity
Hadewych J.M. ter Hofstede
David M. Burger
Peter P. Koopmans
The Netherlands Journal of Medicine 2003; 61:393-403.
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Abstract
In the last decade the use of antiretroviral therapy has lead to dramatic 
improvement in the prognosis of HIV-infection. However, in the long term 
the use of combination antiretroviral therapy is frequently associated with side
effects. Two major problems concerning adverse events are redistribution of body
fat (the syndrome of lipoatrophy and/or lipodystrophy) and toxicity related to
mitochondrial damage. In a large proportion of patients the fat redistribution 
is accompanied by development of insulin resistance and elevated plasma lipid
concentrations. This review will focus on the possible pathogenesis and the 
clinical consequences of these side effects.
20
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Introduction
Since the introduction of highly active antiretroviral therapy (HAART) in HIV-infected
patients, morbidity and mortality due to HIV-infection have been dramatically
decreased 1. Although resistance to antiretroviral therapy is an important issue,
toxicity is becoming a large problem. In the ATHENA cohort the major reason to
switch antiretroviral therapy is toxicity, this is 44-58% in patients on their first
regimen and 56% on subsequent regimens 2. Since HIV cannot be cured, chronic
therapy is needed to suppress HIV-replication, which increases the risk of adverse
events. The benefits of HAART have led to a great number of HIV-patients receiving
antiretroviral therapy 3-5. One of the major problems at the moment is change in
body composition due to fat redistribution; the syndrome of lipoatrophy and/or
lipodystrophy 6;7. 
In this review we will discuss two major groups of antiretroviral therapy-related
toxicity: the lipodystrophy-lipoatrophy syndrome with metabolic changes and
mitochondrial toxicity. Another important group of antiretroviral therapy-related
toxicity is (severe) hypersensitivity with systemic reactions; this will not be 
discussed here. 
Pathogenesis and predisposing factors
Lipodystrophy, lipoatrophy and metabolic disturbances 
One of the most expanding problems, which have been underestimated in the
beginning of HAART introduction, is discussed here. Exposure to antiretroviral
drugs has been associated with the development of significant metabolic adverse
effects such as hyperlipidaemia, hyperglycaemia and insulin resistance with 
diabetes mellitus, peripheral fat wasting (lipoatrophy) and central adiposity
(lipohypertrophy). Fat loss on the extremities, buttocks and in the face together
with localised deposits of fat, particularly in the abdomen, breasts or neck region
(Buffalo hump), is very stigmatising for patients on HAART (picture 1-6) 8-13. 
The prevalence of lipodystrophy varies widely and has been estimated at 7-84%
among adult patients. A prospective cohort study from 1996 till 1999 found the
following incidences: any lipodystrophy 11.7, lipodystrophy with subcutaneous
lipoatrophy 9.2 and lipodystrophy with central obesity 7.7 per 100 patient years.
Data from the Dutch ATHENA cohort including 1952 patients, demonstrated 261
patients who developed lipodystrophy/lipoatrophy. The incidence rate was 6.2 
per 100 person years with a four-year cumulative incidence of 25% 14;15. However,
most lipodystrophy studies included HIV-positive Caucasian men. The incidence 
of lipodystrophy in other than Caucasian subjects is not well studied. One study
showed that lipodystrophy was only seen in 3.5% of a cohort of Koreans 16. 
The authors of the LIPOCO study, evaluating fat distribution by computed tomography
and metabolic changes in patients on antiretroviral therapy, suggested that there
are three major types of fat distribution. First of all the lipoatrophy syndrome 
(fat depletion), which may be related to stavudine use, second a mixed or fat
redistribution syndrome related to an unusual side-product of effective virus-
control, and finally a subcutaneous adiposity syndrome reflecting increase in
21
Chapter 1
proefschrift def  10-11-2008  13:55  Pagina 21
calorie intake (often due to diet prescriptions when using some types of PIs) 10. 
Recent reports highlight the fact that lipodystrophy, mainly the lipoatrophy
component, is primarily linked to NRTI therapy, while dyslipidaemia and insulin
resistance are more readily associated with PI therapy. Although risk factors for
this syndrome are not exactly known, the following factors have been suggested
to play a role: low body weight before start of HAART, elevation of C-peptide and
fasting triglyceride concentrations early in therapy, female gender, age >40 years,
baseline viral load >100.000 copies/ml, white ethnicity, duration of HAART 
and the use of a HAART regimen containing stavudine and combinations of PIs
(especially saquinavir and ritonavir) 10;14;17;18. Lipodystrophy occurs frequently
in regimens including NRTIs and is rare in NRTI sparing regimens. Several studies
confirmed the observation that not only PIs but also the use of NRTIs contribute to
22
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Picture 1-6   Patients with lipodystrophy.
1 Peripheral fat loss arm (lipoatrophy) 2-3 Peripheral fat loss legs (lipoatrophy)
4 Peripheral fat loss buttocks (lipoatrophy) 5 Central fat accumulation (lipohypertrophy)
6 Facial fat wasting (lipoatrophy)
1 2 3 4
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the development of lipoatrophy/lipodystrophy, especially when hyperlactataemia
occurs, which is often seen in patients on stavudine 6;9;10;19;20. The risk to develop
lipodystrophy was assessed in a study with 158 HIV-infected patients of whom 113
received a PI containing regimen and 45 were never treated with a PI. Predictors
of subsequent lipodystrophy severity included weight before PI therapy, duration
of therapy and fasting triglyceride and C-peptide concentrations on 
therapy. Lipodystrophy was very common and even progressive in most cases,
after two years of HAART with a PI 17. In contrast to a prospective cohort study
following almost 500 patients for 18 months, in which the risk factors for 
developing lipoatrophy/dystrophy were multifactorial and overlapping and could
not be ascribed to the duration of exposure to a particular antiretroviral drug 14. 
Adipose tissue changes
Different aspects of adipose tissue disturbances have been postulated in the
development of lipodystrophy/lipoatrophy. One of the hypotheses of this syndrome
is that it occurs due to inhibition of lipid and adipocyte regulatory proteins that
have partial homology to the catalytic site of HIV-1 protease, to which PIs all bind.
PIs are suggested to inhibit CRABP-1-modified and cytochrome P450-3A-mediated
synthesis of cis-9-retinoic acid and peroxisome proliferator-activated receptor
type gamma (PPAR-γ) heterodimer 21. The inhibition increases the rate of apoptosis
of adipocytes and reduces the rate at which pre-adipocytes differentiate into
adipocytes, reducing triglyceride storage and increasing lipid release. PI binding to
low density lipoprotein receptor related protein would impair hepatic chylomicron
uptake and endothelial triglyceride clearance, resulting in hyperlipidaemia and
insulin resistance 6;17;22. Another factor suggested to play a role in lipodystrophy is
the transcription protein sterol regulatory element binding protein 1 (SREBP1).
SREBP1 is necessary for adipocyte differentiation. In vivo investigation of fat tissue
in HIV-patients with lipoatrophy versus HIV-negative healthy controls, demonstrated
a higher proportion of small adipocytes and a reduced expression of SREBP1 in
patients with lipoatrophy 22. 
Recent investigations show the role of the autonomic nervous system in regulation
of adipose tissue. Parasympathetic stimulation of adipose tissue results in glucose
and free fatty acid (FFA) uptake, resulting in an increase of adipose tissue.
Autonomic neurons in the brainstem or the spine are able to innervate abdominal
and subcutaneous fat tissue. A misbalance in the autonomic nervous system could
lead to a different distribution of fat tissue intra-abdominal and subcutaneous,
leading to central fat accumulation and peripheral fat loss as seen in the lipodys-
trophy/lipoatrophy syndrome in HIV-infected patients 23. 
Endocrine changes
In addition, endocrine changes have been revealed in lipodystrophy. The natural
course of HIV-1 infection is associated with an increase in whole body lipolysis
and an increase in resting energy expenditure (REE) without an increase in 
catecholamines (normally stimulators of these processes). However, in patients
with lipodystrophy, plasma concentrations of norepinephrine have been found 
to be increased, indicating increased sympathetic activity. In the same study,
lipodystrophy patients had a lower REE compared to HIV-patients without lipo-
23
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dystrophy. HAART-associated lipodystrophy is therefore suggested to have 
only minor effects on lipolysis induced by HIV-infection itself, as a result of
concomitant sympathetic stimulation of adipose tissue 24. Also an imbalance
between peripheral lipolysis and lipogenesis, both regulated by cortisol and 
dehydro-epiandrosterone, has been hypothesised to play a role in lipodystrophy.
Furthermore, subcutaneous adipocyte apoptosis has been found in lipoatrophic
areas of HIV-patients treated with PIs 25;26. 
Insulin resistance in antiretroviral therapy–associated lipodystrophy has been
attributed to impaired glucose transport and phosphorylation. PIs interfere with
glucose metabolism in muscle and adipocyte cells, leading to an increase of basal
lipolysis. PIs have also been found to directly inhibit the activity of GLUT4, an
important cellular glucose transporter, which is generally thought to be the major
contributor to insulin-stimulated glucose uptake in adipocytes and skeletal muscle.
GLUT4 inhibiton by PIs is thereby leading to a decrease in insulin-stimulated 
glucose uptake 27-29. 
Mitochondrial toxicity
NRTI-associated mitochondrial toxicity has also been postulated to play a role 
in antiretroviral therapy related lipodystrophy 19;20;30. Investigation of muscle
mitochondria in HIV-patients with lipodystrophy, have shown abnormalities in
mitochondrial respiratory chain complexes, mtDNA and mitochondrial morphology
suggestive for mitochondrial dysfunction 31. Adipocyte mitochondria have been
studied in HIV-infected patients on NRTIs, therapy-naive patients and healthy
controls, revealing mtDNA depletion and mitochondrial proliferation in adipocytes
in the first group 32;33. 
Cardiovascular risk of antiretroviral therapy
Lipodystrophy with peripheral lipoatrophy is mostly seen in HIV-infected patients
receiving HAART and therefore not likely associated with HIV-infection itself.
Furthermore, the occurrence and severity of the syndrome is independent of HIV
load. Even after short-term therapy with antiretroviral drugs, metabolic changes
have been observed. In a recent study in which healthy volunteers were treated
with indinavir, insulin resistance was found already after four weeks of drug use 34. 
Prior to the availability of protease inhibitor therapy, endothelial dysfunction,
hypercoagulability, hypertriglyceridaemia and abnormal coronary artery pathology
were associated with HIV-infection. This was even seen in children and young
adults. Autopsy reports showed major atherosclerotic lesions in HIV subjects in 
the absence of traditionally cardiovascular risk factors. A cohort of over 5000 HIV-
patients in the US followed between 1993 and 2002, showed an increase in
myocardial infarctions after the introduction of protease inhibitors in 1996 35. 
In contrast, a retrospective analysis of a cohort of 36.000 HIV-infected patients
between 1993 and 2001, demonstrated a decline in the rate of admissions for 
cardiovascular or cerebrovascular disease from 1.7 to 0.9 per 100 patient-years. 
The authors did not find a relation between the use of NRTIs, NNRTIs or PIs and
the cardiovascular and cerebrovascular events. Antiretroviral therapy was associated
with an overall decrease in death from any cause 36. The DAD study assessed 
the risk of cardiovascular disease in HAART-treated patients in a prospective
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multinational cohort study including around 17.000 subjects. Data from this 
study indicate that NNRTIs and PIs (and especially in combination) are associated
with a lipid profile known to increase the risk of coronary heart disease. This was 
particularly seen in older patients with normalised CD4 counts and suppressed
HIV-replication 37.
Plasma markers that play a role in endothelial function have been shown to be
significantly elevated in HIV-patients (von Willebrand factor, tissue plasminogen
activator, β2-microglobulin and soluble thrombomodulin). Levels of these markers
have been found to be related to the stage of HIV-disease and may be proportional
to the viral load. The course of vascular disease may be accelerated in HIV-infected
patients because of atherogenesis stimulated by HIV-infected monocyte-
macrophages, possibly via altered leukocyte adhesion or arteritis. In recent
literature, a relation between chronic inflammation and atherosclerosis has 
been postulated. In this light, chronic HIV-infection with the occurrence of
co-infections (opportunistic or not) makes subjects prone for atherogenic 
disturbances. In addition, insulin resistance, hypercholesterolaemia and the fat
redistribution syndrome (increase of visceral fat) associated with HIV therapy, 
may exacerbate these HIV-associated atherosclerotic risk factors 22;38-40. Especially
protease inhibitors are known to interfere with lipid and glucose metabolism
resulting in insulin resistance with hyperglycaemia, hypertriglyceridaemia and
elevated total cholesterol (HDL-cholesterol is often reduced) 35;41. However, lipid
changes have also been seen in patients on efavirenz. Moreover, NRTIs may play
a significant role in a synergistic effect on these metabolic changes. 
Overall, there are conflicting data on cardiovascular effects of HAART. The growing
concern that the metabolic complications associated with HIV and antiretroviral
therapy may lead to accelerated coronary artery disease has to be evaluated in
large prospective trials with long-term follow up. Till then, monitoring traditional
cardiovascular risk factors and risk factors associated with HAART such as dys-
lipidaemia, glucose levels and visceral fat accumulation in HIV-patients is justified
(table 1). Before the introduction of HAART, AIDS was still a disease resulting in
death often within two years, making treatment of opportunistic infections 
the most important goal in therapy. With increase in life expectancy, the 
concern of other risk factors for disease in the near future such as cardiovascular
diseases, is rising 22;35;36;42-44. 
25
Chapter 1
table 1   Risk factors for atherosclerosis in HIV-patients on HAART.







Increased plasminogen-activator inhibitor type I
Increased apolipoprotein B
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Toxicity associated with mitochondrial damage
Clinical symptoms that might occur during NRTI therapy are: (cardio)myopathy,
neuropathy, pancreatitis, hepatic steatosis and lactic acidosis (table 2). These
adverse events mostly occur after at least three to four months of NRTI treatment.
The clinical symptoms resemble symptoms that occur in paediatric patients with
congenital mitochondrial diseases. 
Incidences are not well known and vary dependent on the analysis: such as neuro-
pathy 12-46%, myopathy 17% and pancreatitis 0.5-7%. The most life-threatening
NRTI related toxic event reported, is lactic acidosis with hepatic failure. It has
been described for zidovudine, didanosine and stavudine. The incidence is 
estimated around 1.3 per 1000 person-years, retrospectively found in a cohort of
antiretroviral drug users 5;20;45-54. This number fits reasonably well with our own
experience, when we found four fatal cases within one year in the Netherlands,
where around 3000 patients are treated with antiretroviral combination therapy
55. Imminent lactic acidosis should be suspected if a patient complains of
malaise, nausea and vomiting, often accompanied by abdominal pain and hyper-
ventilation, followed by rapid liver failure and uncontrollable arrhythmias. 
The common pathway of this NRTI toxicity is induced mitochondrial dysfunction.
NRTIs are supposed to interfere with an enzyme (polymerase γ), essential for the
synthesis of mitochondrial DNA strands. The triphosphate compounds of the
nucleoside analogues inhibit polymerase γ in two ways; direct inhibition of mtDNA
polymerase γ without NRTI incorporation or chain termination by incorporation of
NRTI triphosphate into mtDNA. Additionally, the incorporated analogues in mtDNA
persist because of inefficient excision resulting in a defective DNA strand.
Combinations of these three mechanisms are possible as well 56. Direct proof
for NRTI induced mitochondrial toxicity has been demonstrated in zidovudine
related myopathy in humans, showing ragged-red fibres and moderate lipid
droplet accumulation and myofilamentous loss without inflammatory
infiltration 46;47;51;54.
In case of toxicity and discontinuation of medication, some tissues seem to 
recover only very slowly. Factors that determine this recuperation capacity are
unknown, but tissues with a low cell turnover like neurones, seem to recover very
slowly and appear to be more vulnerable for this kind of toxicity. An example is
NRTI induced neuropathy that can last for months after NRTIs have been stopped. 
Another striking feature of the NRTI toxicity is its apparent tissue specificity:
myopathy can be caused by zidovudine, but hardly by any of the other NRTIs and
conversely, neuropathy and pancreatitis are common features in treatment with
zalcitabine, didanosine and stavudine, but not with the other NRTIs (table 2). 
A possible explanation for this phenomenon of apparent tissue specificity is the
so-called polymerase γ hypothesis, which states that four factors contribute to an
effective inhibition of DNA polymerase γ by a certain NRTI at a special tissue level.
These factors are: pharmacodynamic capability to enter the target cells, the right
cellular nucleoside kinases to triphosphorylate the NRTI, inhibition of DNA
polymerase γ by the triphosphorylated NRTI either by serving as a competitive
(ineffective) alternate substrate or by chain termination of the nascent mtDNA
strand (non-competitive) and finally metabolic reliance on oxidative 
phosphorylation by the target tissues 5. 
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At present, the reason why some individuals suffer from mitochondrial toxicity is
not clearly understood, although several factors have been identified to play a
role in this mechanism of toxicity. As in congenital mitochondrial diseases this
mitochondrial impairment might have a genetic basis. Patients with suboptimal
mitochondrial function due to inherited mitochondrial DNA (mtDNA) mutations or
deletions, with no symptoms yet, might be more susceptible to develop severe
dysfunction of mitochondria on NRTI therapy. In a comparable fashion, ageing 
will result in increasing mitochondrial dysfunction, since mutations in mtDNA
accumulate in time and repair mechanisms in mitochondrial DNA replication are
limited compared to nuclear DNA replication. Elder people might therefore be
more susceptible than younger. A certain time span appears to be necessary
for the accumulation of toxic effects. Consequently, long-term exposure to 
antiretroviral nucleoside analogues is likely to result in symptomatic mitochondrial
dysfunction. Accumulative toxicity with mitochondrial toxicity due to prior NRTI
use is also seen. Another predisposing factor might be the patient’s nutritional
state. Biochemical reactions in mitochondria depend on a large scale of vitamins,
co-factors and substrates. In malnourished patients there might be a deficiency
for these co-factors, in this way contributing to impaired mitochondrial function 5;55. 
Diagnosis 
Lipodystrophy, lipoatrophy and metabolic disturbances
The diagnosis of this syndrome is difficult and is based on objective and 
subjective parameters such as physical examination with measurement of hip
waist ratio, presence of fat disposition/loss and visible veins on the extremities
together with patient’s report of a changed body composition. The HIV
Lipodystrophy Case Definition Study Group evaluated a model to diagnose lipodys-
trophy. This model included a score system for age, sex, duration of HIV-infection,
HIV-disease stage, waist: hip ratio, anion gap, serum HDL-cholesterol concentra-
tion, trunk: peripheral fat ratio, percentage of leg fat and intra-abdominal: 
extra-abdominal fat ratio. By using this score the diagnosis lipodystrophy had 
a sensitivity of 79% and a specificity of 80%, which is far more than in scores 
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table 2   Adverse events in NRTIs/NtRTI associated with mitochondrial toxicity.
AZT 3TC d4T ddI ddC ABV TFV*
Anaemia + - - - - - -
(Cardio)myopathy + - - - - - -
Neuropathy - - + + + - -
Pancreatitis - +/- - + - - -
Hepatic steatosis + - + + + - -
Lactic acidosis + - + + + - -
* = NtRTI (nucleotide reverse transcriptase inhibitor), AZT = zidovudine, 3TC = lamivudine, d4T = stavudine,
ddI = didanosine, ddC = zalcitabine, ABV = abacavir and TFV = tenofovir.
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using only clinical or metabolic variables 57.
Lipoatrophy/dystrophy with lipid and glucose disturbances have been studied 
by means of blood measurements, CT (computed tomography) scans, DEXA scans
and Body Impedance Amplitude (BIA) in combination with weight and 
measurement of subcutaneous fat. A problem with this syndrome is the 
subjective part of it; changes in body composition experienced by the patients
cannot always be evaluated by standard tests 58-60. Changes in fat distribution
have been objectively confirmed by dual energy X-ray absorption (DEXA) and 
computed tomography. However, DEXA and CT scanning cannot demonstrate 
a change in all aspects concerning the lipoatrophy/lipodystrophy syndrome. 
Facial lipoatrophy, one of the most distressing features of the syndrome, 
cannot be measured in this way 61. In addition, sonography can be considered 
as an additional tool to quantify regional fat distribution. The measurement of
subcutaneous facial and arm fat seems to be simpler, less variable and more 
discriminative to diagnose abnormal regional fat distribution than that of
intra-abdominal fat 62. 
Toxicity associated with mitochondrial damage
Mitochondrial disease are clinically heterogeneous ranging from mild myopathy to
early fatal multi-system disease. Clinical chemical and metabolic results of body
fluids like increased lactic acid and alanine concentrations point to a mitochondrial
disturbance. If so, evaluating those organs and tissues with a high-energy
demand, like brain, the eyes, the heart and skeletal muscle is warranted. For 
this a variety of imaging and electrophysiological studies can be performed. 
Final diagnosis can be reached by biochemical, histological, histochemical and
molecular studies in muscle biopsy samples 63.
Histology is the only method to demonstrate mitochondrial disorders definitely. 
It is an invasive examination and the biopsy site has to be targeted to the tissue
affected. For instance, in muscle biopsies the difference between HIV myopathy
and AZT induced myopathy can be established. The presence of ragged-red fibres
and myofilamentous, is characteristic for an acquired mitochondrial related
myopathy. Damaged mitochondria can be seen with electron microscopy, showing
swollen mitochondria with disruption and fragmentation of cristae, cristallic
inclusions and lipid droplets. However, tissue biopsies are not useful as screening
tests and not every tissue can be sampled 5;64.
For more then a decade specific knowledge of mitochondrial dysfunction has
been obtained during zidovudine induced myopathy by evaluating cytochrome c
oxidase histochemical reaction in muscle biopsies 51;65;66. Cytochrome c oxidase (COX),
is an enzyme essential in complex IV of the mitochondrial respiratory chain.
Deficiency of this enzyme was found in all patients with AZT-related myopathy
and in the majority of AZT treated patients, however, without myopathy. In 
contrast, no deficiency was detected in patients with HIV-related myopathy. 
COX deficiency was found in patients with full-blown AZT myopathy as well as in
myopathic tissue from asymptomatic AZT recipients with only histological changes
characteristic of AZT myopathy 46;67-69. Histochemical reaction for COX could there-
fore be a marker of AZT induced mitochondrial toxicity in HIV-infected patients.
Disadvantages of mitochondrial function tests are the invasive character of these
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tests and the results do not always correlate with the clinical picture. 
NRTI induced hepatic steatosis and neuropathy are diagnoses often detected by
exclusion of other possibilities. Histological examination of the liver reveals
macrovesicular steatosis without necrosis, in contrast to, steatosis induced by
other toxic agents and diseases, which show a microvesicular pattern with 
necrosis. Additional histochemistry has to be performed to exclude infectious
causes. The diagnosis neuropathy can be achieved by electromyography (EMG);
however this does not discriminate between HIV and other causes. 
Less invasive tests, such as blood tests, are easier to perform and therefore, might
be more useful. As a result of mitochondrial dysfunction, pyruvate can only be
metabolised into lactate, which leads to an increased lactate and lactate/pyruvate
ratio. Determination of blood lactate/pyruvate ratio (L/P) is used as diagnostic
screening method in patients with mitochondrial diseases. Chariot et al performed
a small pilot study in 20 HIV-infected patients with AZT induced myopathy 70;71.
Although elevated lactate levels have been described in patients suspected from
mitochondrial toxicity, not all patients with mitochondrial toxicity develop hyper-
lactataemia and lactataemia does not always result in lactic acidosis. Zidovudine,
didanosine and stavudine have all been described to cause lactic acidosis 72-74. 
In addition, several studies found elevated lactate levels more frequently in
stavudine containing regimens. Hyperlactataemia in patients on stavudine is
noticeable and not always directly related to adverse events 75-82. Interestingly,
serum lactate analysis in a group of our own patients revealed the highest lactate
values in patients with presumed NRTI-related neuropathy. This is consistent with
a recent study using serum lactate levels in distinguishing between HIV- and
NRTI-associated neuropathy 83. Overall, asymptomatic mild hyperlactataemia is a
rather common feature of antiretroviral therapy. In recent publications the use of
lactate to monitor complications of antiretroviral therapy has been discussed
75;78;79;84-86. Routine lactate measurement is not recommended; a difference has
to be made between symptomatic and asymptomatic hyperlactataemia and lactic
acidosis 82. Mild asymptomatic hyperlactataemia (lactate levels of ≥2500 µmol/L)
requires careful monitoring but no immediate action. Symptomatic hyper-
lactataemia and lactate levels above 5000 µmol/L are clinically relevant and 
need intervention. It is advisable to check lactates in patients with NRTI-related
neuropathy, hepatic steatosis or elevated transaminases, myopathy and in case 
of extreme fatigue, unexplained nausea, vomiting, dyspnoea or abdominal pain.
Patients with hyperlactataemia should be closely monitored and in case of
increasing lactates or lactic acidosis, nucleoside analogues should be discontinued
64;76;87;88.
Another option to study mitochondrial toxicity is to measure mitochondrial DNA
(mtDNA) contents. In vitro studies have been performed in different cell lines
showing time- and dose dependent mtDNA depletion in cells incubated with 
zalcitabine, didanosine and stavudine in combination with an increase in lactate
production. This effect is also seen in zidovudine treated cells however to a lesser
extent. Lamivudine and efavirenz did not affect any of these measurements. In
conclusion, NRTIs (except lamivudine) can inhibit mtDNA polymerase γ and cause
termination of synthesis of growing mtDNA strands and mtDNA depletion, however
the propensity to injure particular target tissues is unexplained 5. 
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In patients with symptomatic hyperlactataemia changes in mtDNA relative to
nuclear DNA in peripheral blood cells were studied. The ratios of mitochondrial 
to nuclear DNA in HIV-patients with symptomatic hyperlactataemia were 68%
lower compared to non-HIV-infected subjects and 48% lower than the ratios 
in asymptomatic HIV-patients. The decline in mtDNA resolved partially after 
discontinuation of antiretroviral therapy 89. Depletion of mtDNA seems at least
to be partially reversible. Patients followed longitudinally, showed a decline in
mtDNA that preceded the increase in lactate levels. In patients on HAART 
(including NRTIs) with peripheral fat wasting (lipoatrophy) mtDNA contents of
subcutaneous fat tissue from the neck, abdomen and thigh were measured. 
The results showed a decline in mtDNA content compared to HIV-patients on 
HAART without lipodystrophy/atrophy, HIV therapy-naive patients and HIV negative
controls. Unfortunately not all studies show consistency. One study showed 
higher mtDNA levels in patients on antiretroviral therapy compared to 
HIV-infected patients without HAART. This suggests mitochondrial recovery
during HAART. Apparently more mechanisms play a role in the mechanism 
of toxicity 65;87;90-96. 
TREATMENT 
Lipodystrophy, lipoatrophy and metabolic disturbances
HAART receiving patients with hyperlipidaemia and diabetes are currently treated
with lipid lowering agents and oral anti-diabetics or even subcutaneous insulin.
Thiazolidinediones such as troglitazone and rosiglitazone have shown to improve
insulin sensitivity and promote adipocyte differentiation in vitro. Small studies
with metformin and thiazolidinediones in HIV-patients with impaired insulin
sensitivity and diabetes during HAART, showed amelioration of antiretroviral 
therapy-associated insulin resistance, improvement of body fat distribution
(increase in lean body mass), a decrease in total body fat and decline of
triglycerides and VLDL-cholesterol 99-101.
Leptin therapy is suggested to be of use in lipodystrophy. A study in mice 
demonstrated a positive effect of leptin replacement with reduction of
ritonavir-induced hypercholesterolaemia, interscapular fat mass and improvement
of liver steatosis. In contrast to the administration of a polyunsaturated fatty acid
diet, which did not alleviate PI-induced metabolic abnormalities 102. Patients with
congenital lipodystrophy have been studied while on chronic leptin therapy. An
improvement of insulin-stimulated hepatic and peripheral glucose metabolism 
in severe insulin-resistance was demonstrated with marked reduction of hepatic
and muscle triglyceride content 103;104. However, the use in HIV-lipodystrophy
has to be proven.
Lipid disorders are treated with statins in case of elevated cholesterol and fibrates
are used in patients with elevated triglycerides. Till now, pravastatine is the statin
of choice since it has no potential to cause rhabdomyolysis or to interact with the
other medication often used in HAART regimens (especially the PIs) 105;106.
Furthermore, traditional risk factors such as age greater than 40 years, positive
family history, male gender and smoking, should be taken into account when
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treating patients with abnormal lipid values and insulin resistance. Also dietary
modifications and exercise are general health measures that have been proven 
to be beneficial in HIV-infected patients with lipodystrophy and for lipid and 
glucose disturbances 8;22;44.
There is conflicting information on whether switching to a PI depleted regimen
reverses the lipoatrophy/dystrophy syndrome and if this leads to lower lipid 
levels and improvement of insulin resistance. There have been a few studies
switching PIs to abacavir, efavirenz or nevirapine showing improvement of
insulin resistance. Overall there seems to be a favourable change in lipid 
concentrations, particularly after switching to nevirapine and abacavir 42;107.
Metabolic disturbances due to HAART appear to be at least partially reversible.
However, improvement of the fat redistribution has not been clearly
demonstrated. The reason for these conflicting data might perhaps be due to 
limitations in study design, patient numbers and duration of follow up. One 
study with PI-treated patients, who presented with lipoatrophy, hyperlipidaemia
and insulin resistance, analysed the switch from a PI containing regimen to 
one containing efavirenz 107-109. Even one year after substitution of efavirenz 
for PIs the lipid profile did not improve nor did it resolve the insulin resistance 
or lipoatrophy. Another study, replacing ritonavir by nelfinavir or nelfinavir/
saquinavir in HAART combinations, led to improvement of triglyceride levels 110.
Decrease of lipids was also seen in a randomised study in which patients were
switched from a PI containing regimen to a combination of zidovudine, 
lamivudine and abacavir 111-113.
Peripheral fat loss can sometimes be treated with implantation of subcutaneous
fat of the patient or synthetic material (bio-alcamid, New Fill® and botulin
toxin); however the results are not always satisfactory. Cosmetic surgery with 
liposuction can be performed in patients with abdominal fat disposition 
and buffalo hump, however it is not clear if the fat accumulation will re-occur 6;114.
Toxicity associated with mitochondrial damage
There is no real treatment for mitochondrial toxicity. Case reports have been
described treating lactic acidosis due to severe HIV-induced mitochondrial 
damage with co-enzyme Q, thiamine, L-carnitine and riboflavin. These substrates
play an important role in mitochondrial biochemical reactions, however it is not
clear what effect they had in these case reports, since antiretroviral therapy was
always discontinued in these cases 82;115-117.
CONCLUSION
Awareness of adverse effects of antiretroviral therapy will help to improve 
strategies to reduce toxicity. Additional assays and tests are needed in order to
predict and prove toxicity. Furthermore, new generations of antiretroviral agents
will have to be discovered to improve adherence by reducing toxicity in patients
on antiretroviral therapy. Finally, still more studies are necessary to get more
insight in the mechanisms of toxicity, since treatment options for all these 
adverse events have been postulated, however none resolved the original problem.
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Abstract
To describe clinical features and predisposing factors attributed to lactic 
acidosis in four HIV-infected patients on long-term NRTI therapy.
All patients had received at least 6-20 months of NRTI containing antiretroviral
therapy: all used d4T, in one combined with 3TC, in the other three with ddI; 
in one hydroxyurea was added. In all, the initial symptoms were gastrointestinal
(nausea and vomiting), followed by tachypnoea preceding the lactic acidosis;
death followed 6–22 days after admission (liver failure and uncontrollable
arrhythmias). Treatment with riboflavin was unsuccessful in one patient. The
only definite risk factor in all cases was NRTI induced mitochondrial toxicity; 
one patient was concomitantly treated for Kaposi sarcoma (with bleomycin 
and vinblastine) and one just recovered from pneumococcal sepsis. None of the
patients had a history of chronic hepatitis B or hepatitis C infection. In all
patients, some sort of toxicity to other previously used NRTIs had occurred earlier. 
Lactic acidosis occurred after months of NRTI therapy in patients who had already
suffered other forms of NRTI toxicity. Concomitant diseases or co-medication
might have aggravated the mitochondrial toxicity of the NRTIs. Screening 
methods to detect mitochondrial toxicity are necessary, since lactic acidosis
occurs rather unexpectedly, with a rapid, fatal course. 
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Introduction
Although the incidence is very low, fatal lactic acidosis with hepatic failure has
been attributed to the use of nucleoside reverse transcriptase inhibitors (NRTIs)
such as zidovudine (AZT) 1-5 and didanosine (ddI) 6;7. Also for stavudine (d4T), 
lactic acidosis has been reported 8-10. This adverse event is believed to be caused
by mitochondrial toxicity and in fact can occur with any of the antiretroviral
nucleoside analogues, except possibly lamivudine (3TC) 11;12. 
In this paper we report four additional cases of fatal lactic acidosis associated
with the use of antiretroviral nucleoside analogues as part of highly active 
antiretroviral therapy (HAART). We compare and discuss the clinical presentation 
of fatal lactic acidosis and analyse possible underlying risk factors which might
have led to the course of this event. 
Case reports
Patient 1
A 25-year-old Ethiopian woman was found to be HIV positive in October 1996.
Because she had a CD4 count of 0.18 x 109/L and a viral load of 60.000 copies/ml,
HAART was initiated. The first combination consisted of zidovudine (AZT), lamivudine
(3TC) and ritonavir, which was later switched to stavudine (d4T), zalcitabine (ddC)
and indinavir. However, after she developed AZT-related anaemia and ddC-related
neuropathy, the HAART was finally set to a combination of d4T (40 mg b.i.d.), 3TC
(150 mg b.i.d.) and saquinavir (1200 mg t.i.d.). After this triple therapy had started
in April 1997, the CD4 count rose to 0.31 x 109/L and the viral load became 
undetectable (<400 copies/ml) in September 1997. In October 1997 the patient
started to complain of nausea and was admitted because of persistent vomiting.
No explanation for the persistent vomiting was found after extensive biochemical,
neurological, endoscopic and radiological examination. Her medication had
already been stopped 4 days before admission. On the 9th day of admission 
biochemical tests revealed severe lactic acidosis (pH 7.04; normally 7.35-7.45,
bicarbonate 4.8 mmol/L; normally 24-28 mmol/L; lactate 9.8 mmol/L; normally
<1.8 mmol/L; not measured on the day of admission) without signs of sepsis.
Further analysis revealed increased ratios of lactate/pyruvate (50; normal <20) 
and β-hydroxybutyrate/acetoacetate (3.5; normal <2). Despite mechanical 
ventilation and bicarbonate dialysis, she developed hepatic failure, inotropic
agents dependent hypotension and arrhythmias (recurrent ventricular tachy-
cardias) and when the clinical course was further complicated by bacterial sepsis
she died on the 22nd day of admission. Autopsy revealed severe hepatomegaly
with microscopically marked cholestasis and moderate, pericentral, micro- and
macrovesicular steatosis. 
Patient 2
A 31-year-old Dutch woman was found to be HIV positive in 1987. In 1992 AZT 
(200 mg t.i.d.) therapy was started because of a CD4 count of 0.03 x 109/L, but
dose reduction was necessary due to AZT-related anaemia (100 mg t.i.d.).
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Furthermore, co-trimoxazole was initiated as prophylaxis for Pneumocystis Carinii
Pneumonia (PCP). In 1994 ddI (125 mg b.i.d.) was added, but hair loss developed
and treatment was switched to ddC (0.75 mg t.i.d.) after 1 month. Since there was
no response in CD4 counts, AZT resistance was presumed and AZT was switched to
3TC (150 mg b.i.d.). She developed paraesthesia mainly in feet and fingers.
Saquinavir was added to the 3TC/ddC combination in February 1996, but the CD4
count remained very low (<0.01 x 109/L) and the first measured viral load was
15.000 copies/ml (September 1996). She had recurrent periods of perianal genital
herpes and developed a cytomegalovirus retinitis, which was initially treated with
ganciclovir, later with foscarnet. In November 1996 the complete antiretroviral
therapy was switched to ddI, d4T and ritonavir. Doses of ddI (200 q.d.) and d4T 
(15 mg b.i.d.) were adjusted to a foscarnet related renal dysfunction. Although
there was an initial viral response after 5 months (<500 copies/ml), virological
failure necessitated alteration of antiretroviral therapy. Because genotypic viral
resistance analysis demonstrated resistance to protease inhibitors and most of
the NRTIs (except ddI and d4T), therapy was switched to nevirapine (200 mg
b.i.d.), ddI, d4T and hydroxyureum (500 mg b.i.d.) in March 1998. The viral load
became undetectable and her clinical condition stabilised. In may 1998 she 
complained of continuous stomach pain and nausea. Antiretroviral therapy was
stopped for 2 days, but within one week she developed a flu-like syndrome, 
followed by two-sided pneumococcal pneumonia with bacteraemia. Despite
effective antibiotic treatment she became hypotensive and metabolic acidosis 
(pH 7.17, bicarbonate 8 mmol/L) evolved. The lactate level was 19 mmol/L and
though the circulation had normalised, these levels remained high (16 to 26
mmol/L) on hemodialysis, with lactate/pyruvate ratios of 64. Complete hepatic
failure became apparent and together with recurrent arrhythmias (ventricular
tachycardia) she died on the 6th day of admission. Autopsy was denied. 
Patient 3
A 42-year old Dutch man was found to be HIV positive in 1984. In 1992 antiretroviral
therapy with AZT (300 mg b.i.d.) was started (CD4 count of 0.18 x 109/L). In 1994
ddC (0.75 mg t.i.d.) was added, but since there was no response, ddC was
switched to 3TC (150 mg b.i.d.). In 1996 Pneumocystis carinii pneumonia was
diagnosed. Leucopenia developed, possibly related to AZT toxicity and AZT was
switched to d4T (40 mg b.i.d.), later supplemented with saquinavir. Because of
virological failure, the antiretroviral therapy was changed to d4T, ddI (400 mg
q.d.) and indinavir (800 mg t.i.d.) in April 1997. After 5 months of treatment with
indinavir no virological response could be observed and indinavir was changed to
nelfinavir, based on genotypic viral resistance analysis (resistance to AZT, 3TC and
most protease inhibitors except nelfinavir). In November 1997 he was admitted to
the hospital because of complaints of malaise, vomiting, abdominal pain and
weight loss. On physical examination he was very cachectic and he had an
enlarged liver. One day later his status deteriorated with a decreased consciousness,
hypotension and a very low temperature. Although septic shock was assumed, all
cultures remained negative. A severe metabolic acidosis (pH 7.10, bicarbonate 4.6
mmol/L) was found with an elevated lactate level of 16.8 mmol/L, maximally 31.2.
Shortly after mechanical ventilation with dialysis and inotropic assistance, 
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complete liver failure developed. He died on the 6th day of admission. Autopsy
showed severe hepatomegaly with microvesicular steatosis, cholestasis and
extended pericentral liver cell necrosis. 
Patient 4
A 37-year old Dutch man was found to be HIV positive in 1990. In 1996 Kaposi’s
sarcoma lesions were detected on the skin of the legs and thorax, and antiretroviral
therapy with AZT (300 mg b.i.d.), 3TC (150 mg b.i.d.) and ritonavir (600 mg b.i.d.)
was started (CD4 count of 0.09 x 109/L). Kaposi’s sarcoma treatment consisted of
radiotherapy and cyclic bleomycin and vinblastine. Adverse events due to ritonavir
(diarrhoea, nausea, and oral paraesthesia) resulted in discontinuation of ritonavir.
Myalgia, which occurred after introduction of AZT, was temporary and disappeared
after 2 months of treatment. In 1997 antiretroviral therapy failed (viral load 110.000
copies/ml, CD4 count of 0.09 x 109/L) and was switched to d4T (40 mg b.i.d.), ddI
(400 mg q.d.) and indinavir (800 mg t.i.d.). With this second antiretroviral regimen
the patient developed d4T-related neuropathy after two months which progressed
the following months with continuation of the drugs. Viral load became
undetectable, while CD4 count remained unchanged. In November 1998 the
patient was admitted because of nausea, vomiting and tachypnoea. Metabolic
acidosis was diagnosed (pH 7.25, bicarbonate 14.1 mmol/L; lactate 21.4 mmol/L)
without signs of sepsis. A pulmonary X-ray was suspect for pneumonia but
microbiological analysis of all cultures remained negative. Due to clinical 
deterioration the patient was transferred to the intensive care unit where
mechanical ventilation, inotropic treatment and dialysis were started.
Nevertheless, multiple organ failure with arrhythmias (supraventricular tachy-
cardias and later ventricular tachycardias) developed and despite admission 
of riboflavin (50 mg) to treat possible nucleoside analogue toxicity, the patient
died on the 10th day of admission. Autopsy was denied. 
Discussion
The four cases of lactic acidosis described, show similarity with respect to clinical
symptoms, antiretroviral therapy and the final fatal course (table 1). The clinical
features of this drug-induced toxicity are characterised by an episode of malaise,
nausea and vomiting, often accompanied by abdominal pain and tachypnoea
(Kussmaul breathing), finally resulting in liver failure and a fatal cardiovascular
collapse with arrhythmias, secondary to metabolic acidosis. Similar symptoms at
the time of presentation have been described for cases with hepatic failure and
lactic acidosis related to treatment with AZT (n=14), ddI (n=3) 1;4;6;7;13 and also
fialuridine, a nucleoside analogue which has been experimentally tested for 
hepatitis B treatment 14. Nucleoside analogue induced mitochondrial toxicity is
the underlying mechanism of lactic acidosis. The triphosphate compounds of the
nucleoside analogues inhibit polymerase γ, an enzyme essential for mitochondrial
replication 11. In contrast, non nucleoside reverse transcriptase inhibitors (NNRTIs)
and protease inhibitors (PIs) have no affinity for polymerase γ; this is due to 
difference in chemical structure. Therefore, they have no potency to interfere with
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mitochondrial replication. 
NRTI-related adverse events are rather common (incidences vary; e.g. neuropathy
12-46%, myopathy 17%, pancreatitis 0.5-7%) 15-20. Fortunately lactic acidosis, the
most severe toxic event, has a low incidence. Although incidence data are not
exactly known, in a retrospective cohort of patients on antiretroviral therapy, the
incidence was estimated around 1.3 per 1000 person-years 21. 
At present, the reason why only some individuals suffer from these events is not
clearly understood, although several factors might play a role in this mechanism
of toxicity. As in congenital mitochondrial diseases this mitochondrial impairment
might have a genetic basis. Patients with suboptimal mitochondrial function due to
inherited mitochondrial DNA (mtDNA) mutations or deletions, with no symptoms
yet, might be more susceptible to develop severe dysfunction of mitochondria on
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table 1   Patients’ demographics.
patient 1 patient 2 patient 3 patient 4
female female male male
25 years 31 years 42 years 37 years
Presenting symptoms nausea abdominal pain malaise nausea
before fatal outcome vomiting nausea vomiting vomiting
tachypnoea vomiting abdominal pain tachypnoea
flu-like syndrome weight loss
Laboratory parameters before fatal outcome
Lactate (<1.8 mmol/L) 9.8-19.9 mmol/L 19 mmol/L 16.8-31.2 mmol/L 21.4 mmol/L
Bicarbonate (24-28 mmol/L) 4.8 mmol/L 8 mmol/L 4.6 mmol/L 14.1 mmol/L
pH (7.35-7.45) 7.04 7.17 7.10 7.25
Previous nucleoside analogues related toxicity




Virological response ++ + - +
Therapy at time of event d4T (6 months) d4T (18 months) d4T (20 months) d4T (13 months)
(duration) 3TC (6 months) ddI (18 months) ddI (7 months) ddI (13 months)
SQV (6 months) NVP (3 months) NFV (1 month) IDV (13 months)
hydroxy-urea 
(3 months)
AZT: zidovudine, ddC: zalcitabine, ddI: didanosine, d4T: stavudine, 
SQV: saquinavir, NVP: nevirapine, NFV: nelfinavir, IDV: indinavir 
* neuropathy in this patient could also be due to vinblastine. 
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NRTI therapy. In a comparable fashion, ageing will result in increasing mitochondrial
dysfunction, since mutations in mtDNA accumulate in time and repair mechanisms
in mitochondrial DNA replication are limited compared to nuclear DNA replication.
Elder people might therefore be more susceptible than younger. A certain time
span appears to be necessary for the accumulation of toxic effects. Consequently,
long-term exposure to antiretroviral nucleoside analogues is likely to result in
symptomatic mitochondrial dysfunction. Apparently, mitochondria have a rather
long half-life: depletion of mtDNA will only be noticed when the existing mito-
chondria are substituted by new mitochondria. These new mitochondria are
defective, due to the lack of mtDNA encoded enzymes. At present, there are no
exact data about the life span of a mitochondrion. The influence of both factors,
genetic predisposition and accumulative toxicity, is a possible explanation for the
appearance of adverse events in the above cases. All patients with lactic acidosis
reported adverse events to prior nucleoside analogues (e.g. neuropathy, myopathy
and bone marrow suppression) and all patients developed this severe acidosis
after at least several months of antiretroviral therapy (table 1). The neuropathy in
patient 4 might also have been related to synergistic toxicity of vinblastine, as 
this agent might cause mitochondrial toxicity as well. Another predisposing factor
might be the patient’s nutritional state. Biochemical reactions in mitochondria
depend on a large scale of vitamins, co-factors and substrates. In malnourished
patients there might be a deficiency for these co-factors, in this way contributing
to impaired mitochondrial function. 
In our four cases no specific diseases in the medical history of these patients
could be kept responsible for the occurrence of the presenting symptoms. 
None of the patients had a history of chronic hepatitis B or C infection. 
However, concomitant diseases or co-medication in the period of admission,
might have aggravated the mitochondrial toxicity. A precipitating factor in patient
2 might have been sepsis, which certainly enhanced the oxidative stress. Almost
all fatal events described in literature occurred during monotherapy with a 
nucleoside analogue. In the patients discussed in this article, there might have 
been a toxic synergism between the nucleoside analogues, especially in patient
2, 3 and 4. 
In patient 2, hydroxyurea might even have enhanced this synergism. 
Up to now, fatal adverse reactions have not been reported for either d4T or 3TC.
Recently reversible hepatic steatosis with lactic acidosis was related to the use 
of d4T 8-10. Known side effects of d4T are peripheral neuropathy and pancreatitis
and as with AZT induced myopathy and ddI/ddC induced neuropathy, these side
effects are believed to be caused by acquired mitochondrial disease 11;12. Although
the above described patients had used several nucleoside analogues for a long time,
they were all on a d4T containing regimen at the presentation of the symptoms.
In patients 2, 3 and 4 ddI might have contributed to the toxicity, as discussed
above. Furthermore, in patient 1 3TC use might have contributed to the toxicity,
although in contrast to the other nucleoside analogues, 3TC shows little inhibition
of mitochondrial DNA synthesis in vitro 22;23.
Since antiretroviral therapy will be used as long-term treatment in many
HIV-infected patients, the occurrence of serious adverse events will increase. 
The chance that prolonged use of any antiretroviral nucleoside analogue might
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precipitate this (irreversible) mitochondrial dysfunction will seriously hamper 
the possibility to control HIV-infection with HAART. More research is necessary to
define predisposing factors responsible for this severe drug toxicity more clearly
and screening methods to detect this toxicity in an early phase have to be 
developed. Moreover, information about mitochondria is required in order to 
gain a clear understanding of their regeneration capacity and to identify whether
there is a point of no return. It is not known whether administration of oxidative 
phosphorylation substrates (i.e. vitamins) might be useful to prevent or treat
severe mitochondrial damage. Therefore, the use of L-carnitine is advised in
treatment with adefovir, a currently investigated NRTI. As long as predisposing
factors and treatment in this syndrome remain unclear, two categories of
patients should be monitored frequently: the ones with adverse events 
to previously used nucleoside analogues and the ones on long-term 
antiretroviral therapy. 
As a result of mitochondrial dysfunction, pyruvate can only be metabolised 
into lactate, which leads to an increased lactate and lactate/pyruvate ratio.
Therefore, measurements of serum lactate and pyruvate demonstrating 
elevated lactate/pyruvate ratios, might indicate early mitochondrial 
dysfunction 24;25. 
These parameters might also be useful to detect mitochondrial damage in 
an early stage, when it is still asymptomatic and possibly reversible. Deviant
bicarbonate levels and acid-base status will only become apparent in a later
stage when lactic acidosis arises. It is crucial to act promptly when the above
described symptoms start to occur since a fatal course will follow shortly.
Antiretroviral therapy should be stopped immediately and supportive care 
has to be started to prevent complications of lactic acidosis and to reduce the 
potential risk of death. In addition, possible beneficial effect in hereditary
mitochondrial diseases has been achieved after supplementary treatment with
vitamins and co-factors. For example, Coenzyme Q10 (CoQ10) and riboflavin have
been used in patients with mitochondrial disorders. However, varying degrees 
of success have been reported in individual cases. It should be stressed that
with these therapeutic options used in mitochondrial disorders, only modest
improvement has been observed. Unfortunately, the course of the toxicity
symptoms and prognosis are difficult to predict and depend largely on the 
type of tissue affected. In HIV-patients successful recovery of nucleoside 
analogue-induced lactic acidosis has been attributed to treatment with CoQ10
and riboflavin 8;26, supporting the hypothesis that metabolic deficiencies 
precipitate this toxicity. Adverse effects from co-factors and vitamins are rare, 
so despite the controversy about efficacy it is advisable to use riboflavin, 
thiamine, CoQ10 and L-carnitine in an attempt to improve the clinical status of
a patient with lactic acidosis in order to enhance survival chances. Dosage 
regimens are uncertain and vary in case reports; therefore a recommendation
cannot be given at present. Because the effect of these co-factors remains 
uncertain, additional support and immediate cessation of the NRTIs is required 
as well. In summary, treatment started early in the course of mitochondrial 
toxicity will achieve better survival 27;28. 
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Abstract
Nucleoside reverse transcriptase inhibitors (NRTIs) used in antiretroviral therapy
may cause mitochondrial toxicity. Mitochondrial dysfunction leads to disturbance
of the glucose metabolism, resulting in an accumulation of L-lactate (L) and
pyruvate (P), with an enhanced L/P ratio. 
We analysed lactate and pyruvate blood samples of patients of our outpatient
department. Aim of the analysis was to detect preliminary mitochondrial 
toxicity in patients on antiretroviral nucleoside analogues, which might result
in disturbances of L, P, L/P ratio, bicarbonate (Bic) or β-hydroxybutyrate/
aceto-acetate (β-HB/AA) ratios. 
Blood samples of L, P, Bic, β-HB and AA were analysed in four groups of subjects.
The first group (A) consisted of patients with presumed NRTI-related adverse
events (n=21), the second group (B) consisted of patients without adverse events
(n=28), the third group (C) were HIV-infected patients without antiretroviral
therapy (n=6) and the last group (D) were healthy controls (n=12). The mean
duration of NRTI treatment was 18 months (range 0 - 78 months). 
The mean lactate level in group A was 2319 µmol/L (SD ± 1231, median 1741
µmol/L), in group B 1257 µmol/L (SD ± 607, median 1087), Group C 1285 µmol/L
(SD ± 451, median 1245 µmol/L) and 951 µmol/L (SD ± 270, median 979) in the
healthy controls. No significant differences in pyruvate, L/P, Bic and β-HB/AA
were seen in the four groups. The mean lactate level in patients on stavudine
was 1980 µmol/L (SD ± 1197) versus 1051 µmol/L (SD ± 395, p=0.01) in patients 
on zidovudine. All patients with lactate values above 2700 µmol/L (8) 
experienced adverse events. 
Lactate levels were higher in patients with presumed NRTI-related adverse
events. Furthermore, HIV-patients receiving a stavudine containing antiretroviral
therapy had higher lactate values than patients without stavudine. Although
routine lactate measurement in all patients on antiretroviral therapy is not
recommended, lactate measurement might be useful for follow up of patients
with presumed NRTI-related adverse events and in patients with lactate levels
above 2500 µmol/L. These patients require extra surveillance to evaluate if
discontinuation of the current antiretroviral therapy is needed. 
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Introduction
Although antiretroviral therapy in human immunodeficiency virus (HIV) infected
patients has proven to be very effective in the suppression of HIV-infection 1 the
efficacy of the drugs has not only resulted in almost complete inhibition of HIV
replication, but also in severe side effects 2. The incidences of these side 
effects are rather high, which has still been accepted because of the severity
of HIV-infection itself. However, drug-safety becomes an even more important
issue with the need for life-long treatment since HIV-infection can still only be
suppressed and not cured. 
The currently used so called highly active antiretroviral therapy (HAART) consists
mostly of a combination of two nucleoside reverse transcriptase inhibitors (NRTIs)
and a protease inhibitor (PI) or non nucleoside reverse transcriptase inhibitor
(NNRTI). NRTIs play a prominent role in antiretroviral therapy. In the years of
experience with NRTIs, the following adverse effects have been recorded: 
(cardio)myopathy (zidovudine, didanosine), neuropathy (stavudine, didanosine,
zalcitabine), pancreatitis (stavudine, didanosine, zalcitabine), hepatic steatosis
and hepatic failure with lactic acidosis (stavudine, zidovudine, didanosine) 3-5.
The underlying mechanism of these adverse effects is supposed to be 
mitochondrial toxicity 6;7. In addition to inhibition of viral reverse transcriptase,
the NRTIs inhibit human DNA polymerase γ, an enzyme essential for the 
mitochondrial DNA replication. In addition, NRTIs may also interfere with 
mitochondrial RNA formation, which has no repair mechanisms. This may
prematurely terminate synthesis of mitochondrial messenger and transfer RNA,
leading to impaired transcription and translation 8. 
In paediatric literature it has been reported that patients with mitochondrial 
diseases have abnormal lactate levels due to a diminished function of the aerobe
reaction. When the mitochondrial function is impaired, the oxidation of pyruvate
cannot take place, and pyruvate will be turned to lactate because this is the 
only possible reaction outside mitochondria. A shift in the pyruvate to lactate
equilibrium will occur, in favour of lactate production. Subsequently, metabolic
acidosis might occur if the lactate production exceeds a certain threshold 6;7;9-14.
In HIV-infected patients on antiretroviral therapy these adverse events usually
only occur after several months of therapy. There seems to be a certain threshold;
passing this threshold results in irreversible damage. Since finally lactic acidosis
might develop, which is potentially fatal and which happens to occur rather
acutely, a laboratory test to detect mitochondrial toxicity in an early and still
reversible phase, is needed.
In this comparative study we analysed the feasibility of lactate (L), pyruvate (P),
L/P ratio, bicarbonate and β-hydroxybutyrate/aceto-acetate (β-HB/AA) ratio 
measurement to test mitochondrial damage. There were four groups:
HIV–seropositive patients on antiretroviral therapy with presumed NRTI-induced
adverse events related to mitochondrial toxicity, HIV-seropositive patients on
antiretroviral therapy without adverse events, HIV–seropositive patients without
antiretroviral therapy and healthy volunteers. 
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Patients and methods
Patients were selected from the clinic population who visited our outpatient
department in the period November 1998 till December 1999. Selection of patients
was at random. They were enrolled in one of the three HIV-subgroups depending
on antiretroviral therapy use and presumed NRTI-related adverse events. Events
were considered NRTI-related if all other causes could be excluded after laboratory
measurements, cultures, radiologic imaging and if necessary electromyography
and biopsy. Healthy volunteers were selected from the normal population and
were screened (medical history, physical examination and laboratory) before
entering the study. 
Group A
The first group consisted of patients with presumed NRTI-related adverse events
(n=21). 
In the patients with presumed NRTI-related adverse events blood samples were
collected within 3 months after the onset of adverse events. The mean duration 
of NRTI treatment was 20 months (range 3-78 months). 
Group B
The second group consisted of patients on antiretroviral therapy without adverse
events (n=28). The mean duration of treatment was 15 months (range 0-46
months).
Group C
The third group was a small group of 6 HIV-infected patients without antiretroviral
therapy (the majority of our HIV-patients are treated with antiretroviral drugs).
Group D
The last group consisted of healthy volunteers (n=12), who served as controls.
Written informed consent was obtained from all subjects. 
Measurements
In all subjects we measured lactate, pyruvate, L/P ratio, bicarbonate and β-HB/AA
ratios. In group A, B and C the samples were collected when patients visited the
outpatient department. In the same period samples from 12 healthy volunteers
were analysed. Population characteristics are depicted in table 1. A standard 
procedure for the venal puncture was followed in every subject. All blood samples
were taken in the morning after a 5 minutes rest and without stowage of the vein
to avoid lactate increase by the procedure itself. 
L-Lactate and pyruvate assay in blood
For quantification of L-lactate and pyruvate in blood, enzymatic assays 
(Roche, Basel Switzerland) with L-lactate dehydrogenase (L-LDH EC 1.1.1.27) were
performed. Before the assays were performed the samples were deproteinised
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with 6 g/L perchloric acid and for the pyruvate assay the perchloric solution was
neutralised with 1.75 mol/L K3PO4 phosphate solution 15. Because the reaction
between L-lactate and pyruvate is an ongoing reaction by means of the lactate
dehydrogenase enzyme (LDH), blood was immediately mixed in a tube containing
perchloric acid (as stated above) to stop this reaction. Then the blood samples
were placed on ice and instantly transported to the laboratory. The normal values
of our laboratory are: L-lactate <1800 µmol/L, pyruvate levels <70 µmol/L, L/P ratio
<18, bicarbonate 24-30 mmol/L, aceto-acetate/β-hydroxybutyrate ratio <0.3.
Statistics
Wilcoxon’s rank sum test was used to detect statistical differences between the
groups. 
Results
A total of 67 samples were analysed, for bicarbonate, β-HB/AA ratio, lactate 
concentrations (table 1 and 2, figure 1), pyruvate and L/P ratio. Bicarbonate 
levels were normal in the groups (data not shown). Also β-hydroxybutyrate/
aceto-acetate ratios were within the normal range and did not show any
differences between the groups (data not shown).
In the group of patients with presumed NRTI-related side effects (group A, table 2)
10 out of 21 patients (48%) had hyperlactataemia (L >1800 µmol/L). These patients
are referred to as ‘symptomatic hyperlactataemia’. In group B (patients with 
antiretroviral therapy without adverse events) 6 out of 28 patients (21%) had 
lactate levels above the upper limit of normal. In the group of HIV-infected
patients still without antiretroviral therapy one patient had an elevated lactate
level (1989 µmol/L). Hyperlactataemia was not found in any of the healthy
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table 1   Population characteristics and L-lactate values.
Group A Group B Group C Group D
Number of patients 21 28 6 12
Age (years) 42±8 42±8 39±8 28±6
range 27-58 25-53 27-48 20-42
Gender Male 17 Male 23 Male 4 Male 11
Female 4 Female 5 Female 2 Female 1
Duration of therapy 20 months 15 months - -
range 3-78 0-46
Median L (µmol/L) 1741 1087 1245 979
Mean L (µmol/L) 2319±1231 1257±607 1285±451 951±270
Range L (µmol/L) 824-5744 440-2644 755-1989 644-1286
L = lactate
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volunteers. Overall the lactate levels were the highest in the adverse event group,
median lactate still within the normal range (1741 µmol/L) with an increased mean
lactate (2319 µmol/L), but there were no statistical significant differences (p 0.07).
The pyruvate levels did not show significant differences, although the mean 
pyruvate levels were slightly elevated (74 µmol/L) in group A. The highest L/P ratios
were seen in group A, although group B and C also showed elevated ratios. Only
one healthy volunteer had an elevated L/P ratio (23.1), the mean and median ratio
were all normal in this group. Elevated L/P ratios were mostly due to a low pyruvate
instead of hyperlactataemia, therefore we consider this measurement not useful. 
Lactate levels in comparison with drug regimens and adverse events
Lactate values per drug regimen are depicted in table 3. The comparison between
the antiretroviral drug regimens is striking. Of the 33 patients on stavudine, 17 had
elevated L-lactate levels and 14 experienced adverse events (14/33; 42%). The mean
lactate level was 1980 µmol/L (median 1832 µmol/L). None of the 12 zidovudine
patients had hyperlactataemia, 7 of them experienced adverse events (7/12; 58%).
In this treatment group the mean lactate level was 1051 µmol/L (median 963
µmol/L). Of the total population of HIV-infected subjects (55 patients) 18 patients
had hyperlactataemia of whom 17 (17/18; 94%) patients were on a stavudine 
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figure 1   L-Lactates in patients with and without adverse events, HIV-infected patients 
without antiretroviral therapy and healthy volunteers; individual levels. 
The line marks the lactate value of 2700 µmol/L. Patients with lactate levels 
≥2700 µmol/L all experienced adverse events. 


















L-lactate comparision between the four groups
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containing regimen and one patient did not use any antiretroviral therapy at all.
Seven of these hyperlactataemia patients had hepatic steatosis (ultrasound or
biopsy). Laboratory evaluation did not reveal an underlying hepatic disease.
Patients were all using NRTIs in combination with PI of NNRTI. Elevated transaminase
levels in one patient with severe liver dysfunction decreased to normal values
after a period of discontinuing HAART. 
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table 2   Characteristics of group A. 
G A AEs L P L/P ART Prior ART Prior NRTI-tox
1 M 47 HS 3134 135 23.2 D4T, 3TC, IDV AZT, ddI, ddC
2 M 42 HS 4232 146 29.0 D4T, ddI, IDV None
3 M 37 HS 1952 45 43.3 D4T, ddI, RTV AZT, ddC, 3TC Np
4 M 36 HS 2219 94 23.6 D4T, ddC, IDV AZT, 3TC
5 M 25 HS 1065 20 53.3 D4T, ddI, IDV + RTV AZT, ddC, RTV (alone)
6 M 44 HS 1340 45 29.8 D4T, 3TC, NFV AZT, ddI, ddC Np
7 M 44 HS 1288 107 12.0 AZT, 3TC, IDV None
8 M 53 Np 4313 75 57.5 D4T, ddI, NVP None
9 M 52 Np 2790 129 21.6 D4T, SQV, RTV None
10 M 43 Np 2832 106 26.7 D4T, 3TC, NVP AZT, ddC Np
11 F 26 Np 5744 117 49.1 D4T, 3TC, SQV, RTV AZT, ddI
12 M 52 Mp 1545 50 30.9 D4T, ddI, IDV AZT, 3TC Pp
13 M 45 Mp 925 34 27.2 AZT, 3TC, IDV None
14 M 35 Mp 901 44 20.5 AZT, 3TC, RTV None
15 M 32 Mp 1613 113 14.3 AZT, 3TC, IDV None
16 F 42 Mp 1122 40 28.1 AZT, 3TC, IDV None
17 M 44 Mp 824 35 23.5 AZT, 3TC, IDV None
18 M 44 Am 1103 25 44.1 AZT, 3TC, IDV None
19 F 33 Np, HS 2787 45 61.9 D4T, 3TC, IDV AZT, ddC, ddI Np
20 M 44 Np, HS 3400 47 72.3 D4T, 3TC, IDV AZT, ddC, ddI Np
21 F 37 Np, Am 1721 55 31.3 D4T, 3TC, NFV AZT Am
HS = Hepatic Steatosis, Np = Neuropathy, Mp = Myopathy, Pp = Pancytopenia, Am = Anaemia G = gender
(M = male, F = female), A = age (years), AEs = adverse events, L = lactate (µmol/L), P = pyruvate (µmol/L) 
Prior ART = Prior antiretroviral therapy Prior NRTI-tox = Prior NRTI toxicity
table 3   Lactate values per drug regimen.
Drug regimens Number of patients Mean L (µmol/L) Median L (µmol/L) 
D4T combinations 33 1980 1832
AZT combinations 12 1051 963
2 PI, no NRTI 3 1061 921
HIV with no ART 6 1222 1176
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Looking at the drug regimens more closely, demonstrated that stavudine/didanosine
combinations revealed the highest lactate levels. There were two patients on a
drug regimen with one NRTI. They received stavudine in combination with two 
PIs. One of these patients had an elevated lactate (2790 µmol/L) and suffered 
from neuropathy. The mean lactate level in the stavudine treated patients was
1980 µmol/L (SD ± 1197) versus 1051µmol/L (SD ± 395) in the zidovudine treated
patients (p=0.01).
The values of lactate per adverse event group are represented in table 4. Striking
are the highest levels of lactate in the neuropathy patients, who were all on
stavudine. Symptomatic hyperlactataemia was mainly seen in stavudine patients.
All patients with lactates ≥2700 µmol/L (8 patients) experienced adverse events
and they were all on a stavudine containing regimen (figure 1). In group C there
were 2 patients with lactates ≥2400 µmol/L. They were both treated with 
stavudine, one of them died of an AIDS-defining disease nine months later 
and the other one developed stavudine induced neuropathy one year later. 
Discussion
Lactate values showed differences between HIV-infected patients and healthy
volunteers, in contrast to bicarbonate, β-HB/AA, pyruvate and L/P ratios, which
did not provide additional information. β-HB/AA ratios stayed within the normal
range and pyruvate L/P ratios were often elevated only due to a low pyruvate
(although still within the normal range) and not as a result of hyperlactataemia.
Only mild to moderate hyperlactataemia occurred, which did not result in low
bicarbonate levels. There is a difference in hyperlactataemia and lactic acidosis, 
in the latter the lactate values are severe (mostly >10.000 µmol/L) and result in
acidosis, which does not occur in mild to moderate lactate increases. In our 
study no subject had a lactate level above 6000 µmol/L. 
Measurements of lactate demonstrated hyperlactataemia mainly in the NRTI-related
adverse event group. Symptomatic hyperlactataemia was found in all patients (8)
with a lactate value above 2700 µmol/L (figure 1). Two patients had hepatic
steatosis, four were suffering from neuropathy and two of them experienced both
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table 4   Lactate values per adverse event. 
AEs Number of patients Mean L (µmol/L) Median L (µmol/L)
Neuropathy 7 3644 3116
Hepatic Steatosis 9 2314 2086
Myopathy 6 1155 1024
Anaemia 2 1412 1412
NRTI
D4T 14 2791 2789
AZT 7 1111 1103
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hepatic steatosis and neuropathy. They were all on a stavudine containing regimen.
Hyperlactataemia in patients on stavudine is noticeable and not always directly
related to adverse events 8;16-23. Interestingly, the separation of adverse events
demonstrated the highest lactate values in patients with presumed 
NRTI-related neuropathy. This is consistent with a recent study using serum 
lactate levels in distinguishing between HIV- and NRTI-associated associated 
neuropathy 24.
Asymptomatic mild hyperlactataemia is a rather common feature of antiretroviral
therapy. In recent publications the use of lactate to monitor complications of anti-
retroviral therapy has been discussed 8;13;20-23;25;26. Routine lactate measurement
is not recommended; a difference has to be made between symptomatic and
asymptomatic hyperlactataemia and lactic acidosis. Mild asymptomatic hyper-
lactataemia requires careful monitoring but no immediate action. However, 
symptomatic hyperlactataemia and lactate levels above 5000 µmol/L are clinically
relevant and need intervention. From our data and literature we suggest that
lactate levels of ≥2500 µmol/L need attention and might indicate therapeutic
problems in the near future 11;19-21;26-28. It is advisable to check lactates in 
patients with NRTI-related neuropathy, hepatic steatosis or elevated transaminases,
myopathy and in case of extreme fatigue, unexplained nausea, vomiting, dyspnoea
or abdominal pain. These latter and non specific symptoms might be the first
signs of sudden (and often fatal) lactic acidosis 11;18;19;29;30. Patients with hyper-
lactataemia should be closely monitored and in case of increasing lactates or 
lactic acidosis, nucleoside analogues should be discontinued 8-10;31. We would
advice to pay especially attention to patients with stavudine-related neuropathy
since we found the highest lactate levels in these patients. 
In our study the duration of antiretroviral therapy was longer in patients with
presumed NRTI-related adverse events than patients without side effects.
Symptomatic patients were more often receiving their second (or more) regimen
with antiretroviral drugs. Both factors are understandable because, mitochondrial
toxicity due to NRTIs is correlated with duration of therapy, prior NRTI therapy and
possibly combined use of PI or NNRTI 8;9;22;32. 
The risk of hyperlactataemia in patients on antiretroviral therapy increases in
patients with drug combinations, which are individually able to induce lactataemia.
The risk of lactic acidosis and occurrence of hyperlactataemia is known for all
approved nucleoside analogues in HIV-treatment 4;16;20;29;33-34. Combinations with
stavudine and didanosine might be of special concern regarding hyperlactataemia
6;22. Although the group is rather small we also found higher lactate levels in anti-
retroviral drug combinations containing both stavudine and didanosine.
Anecdotal reports indicate that the use of NRTI in combination with PI or NNRTI
contribute to hyperlactataemia 8;22;35. The widely use of HAART, with simultaneous
use of NRTI(s) with PI or NNRTI might be an additional risk factor in the occurrence
of hyperlactataemia. Although the mechanism is not fully explained, a possible
explanation might be that PIs and NNRTIs interfere with liver function. NNRTIs are
known to cause liver function disorders. PIs are able to interfere with glucose and
lipid metabolism resulting in insulin resistance, hyperglycaemia and hyper-
lipidaemia and finally hepatic steatosis. Lactate clearance depends on liver 
function and to a lesser extend on the kidneys. Thus, hyperlactataemia can be
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due to all antiretroviral medication by increased extra-mitochondrial production
in case of NRTI related mitochondrial toxicity or by decreased clearance in case of
hepatic or kidney dysfunction 2;32;34-37. All our patients with hyperlactataemia
were treated with combinations of NRTI(s) with PI or NNRTI. We realise that PI and
NNTRI use might have contributed to hyperlactataemia in case of hepatic steatosis.
Hyperlactataemia due to impaired kidney clearance was not demonstrated; no
abnormalities in creatinine were seen (data not shown).
Besides the influence of NRTIs on mitochondria, other factors might also influence
mitochondrial function resulting in hyperlactataemia. Biochemical reactions in
mitochondria depend on a large scale of vitamins, co-factors and substrates. Case
reports have been described treating lactic acidosis due to severe NRTI-induced
mitochondrial damage with co-enzyme Q, thiamine, L-carnitine and riboflavin.
Although it is likely that metabolic deficiencies may provoke mitochondrial toxicity,
it is not clear what effect can be expected by administering these substrates, since
antiretroviral therapy was always discontinued in these cases 6;9;10;24;38-40. 
In conclusion, hyperlactataemia might indicate early mitochondrial toxicity, 
however other factors might also play a role in this mechanism. More experience
from prospective trials will be needed in order to evaluate the meaning and 
feasibility of L-lactate measurements in HIV-infected patients on antiretroviral
therapy. 
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Chapter 4
Oral glucose loading for detection of mitochondrial toxicity
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Abstract
Nucleoside reverse transcriptase inhibitors used in antiretroviral therapy may
cause mitochondrial toxicity. Mitochondrial dysfunction leads to disturbance of
the glucose metabolism, resulting in an accumulation of L-lactate. We tested 
the hypothesis that an oral glucose tolerance test (OGTT) can be used to detect
mitochondrial toxicity in patients on antiretroviral nucleoside analogues.
An OGTT was performed in 30 subjects: 16 HIV-infected treated patients without
adverse events (group 1) and 14 HIV-infected patients with adverse events related
to nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity
(group 2). Lactate was measured at baseline and 60 and 120 min after glucose
loading. 
At all time points the lactate levels were higher in the adverse events group
compared to the other group, with the highest levels of lactate at t=60 min 
(mean 1912 µmol/L, SD ± 609); mean lactates in the group without adverse events
was 1429 µmol/L (SD ± 464). When levels above the upper limit of normal of 1800
µmol/L were used as an indication for mitochondrial toxicity, the sensitivity and
specificity were 57% and 81%, respectively. The area under the ROC curve was
0.75. For L-lactate levels >2000 µmol/L the specificity was 90%. 
An OGTT with measurement of lactate at baseline and one hour after glucose
loading can detect (occult) hyperlactataemia in patients with mitochondrial
impairment. From our study we suggest to perform an OGTT as an additional test
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Introduction
Highly active antiretroviral therapy (HAART) has altered the prognosis of HIV (human
immunodeficiency virus) infected patients dramatically. This means that HAART,
usually a combination of two nucleoside reverse transcriptase inhibitors (NRTIs) as
a backbone and one protease inhibitor (PI) or non nucleoside reverse transcriptase
inhibitor (NNRTI), has converted lethal HIV-infection into a chronic disease. 
Unfortunately, antiretroviral therapy (ART) is often accompanied by severe adverse
events, especially after long term use. Since HIV-infection can only be suppressed
and not cured, patients need life-long treatment, which underscores the 
importance of drug safety.
NRTIs play a prominent role in antiretroviral therapy. After years of experience 
with these NRTIs, a series of adverse effects have been observed: myopathy, 
cardiomyopathy, pancreatitis, anaemia, hepatic steatosis, peripheral neuropathy,
lactic acidosis and lipoatrophy/hypertrophy 3;5;10. Mitochondrial toxicity has been
identified as key factor in these adverse events 7;8;15;29. Dysfunction of the OXPHOS
system alters mitochondrial and cytoplasmic redox-status, leading among others,
to a shift in the pyruvate to lactate equilibrium, in favour of lactate 5;17.
Subsequently, even metabolic acidosis might occur if the L-lactate level in serum,
exceeds a certain threshold. Usually these adverse events only occur after several
months of therapy. Since lactic acidosis tends to occur rather acutely, a test to
detect mitochondrial toxicity in an early and perhaps still reversible state is needed.
Normally glucose is metabolised to pyruvate. Oxidation of pyruvate takes place in
the mitochondrion while the anaerobic reaction, producing lactate, takes place
outside the mitochondrion. Therefore, in mitochondrial dysfunction pyruvate 
will be metabolised via the alternative pathway with production of lactate. Since
in paediatric medicine glucose loading is used for early detection of inherited
mitochondrial diseases, we wondered whether an oral glucose tolerance test
(OGTT) could be useful in patients treated with antiretroviral therapy for 
detection of mitochondrial toxicity 16. 
Materials and Methods
Study design
Between April 2001 and February 2002 57 HIV-patients (able to communicate 
in Dutch) visiting our outpatient department were asked for the OGTT study; 
30 patients were enrolled. We investigated 2 groups of individuals (total of 30
subjects): 16 HIV-infected patients with antiretroviral therapy who did not suffer
from adverse effects (group 1); and 14 HIV-infected patients with adverse effects
(AEs) related to mitochondrial toxicity (group 2). At the time of the OGTT the side
effects in group 2 were neuropathy (n=10) and hepatic steatosis (n=4). 
At our outpatient department all patients are explicitly questioned about
possible adverse events (i.e. paraesthesia, muscle pain, abdominal pain and 
body changes). Possible adverse events were evaluated by means of additional
laboratory tests, radiological examination, endoscopy, electromyography or biopsy,
if necessary (in patients with hepatic steatosis). Patients with infectious hepatitis,
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alcohol abuse, diabetes or medication that might induce hyperlactataemia, were
excluded. Events were recorded as a side effect if no other cause was identified.
In the four patients with hepatic steatosis the suspected NRTI was finally stopped
(after the OGTT) resulting in decrease of transaminases. One patient was 
rechallenged with the toxicity-associated NRTI, which resulted again in liver
abnormalities. In six patients with neuropathy, stavudine was finally stopped
(after the OGTT) resulting in diminishing paraesthesia, however not all patients
experienced complete relieve of neurological symptoms. There was no difference
in family history of diabetes or body mass index (BMI) between the two groups
(nobody had a BMI >27 kg/m2).
Subjects were screened by means of history taking, physical examination and
blood tests. The research protocol was approved by the ethic committee of the
University Medical Centre Nijmegen and written informed consent was obtained
from all subjects. Characteristics of the groups are depicted in table 1 and 2.
Oral glucose tolerance test (OGTT)
The oral glucose tolerance tests (OGTTs) were performed at the outpatient clinic 
in the morning. The OGTT was performed after a 12 h overnight fast and at least
5 min after the placement of a peripheral intravenous catheter, in order to 
prevent enhanced lactate levels by stress. For the same reason no tourniquet was
used. Patients were instructed not to use alcohol the day prior to the test and to
avoid exercise prior to and during the test. After the first blood sample was taken 
(t=0), patients had to drink a solution of 75 g glucose in 250 ml water within 3
minutes, to create an effective glucose load. At t=0 minutes blood samples were
taken for glucose, lactate, lipids and insulin. At t=60 and 120 minutes glucose and
lactate were measured. Cholesterol and triglycerides were also measured at t=120
min. At the time of the OGTT patients were still suffering from the AEs. 
L-Lactate 
For the measurement of lactate special vacuum tubes with perchloric acid were
made in the laboratory. Blood and perchloric acid (6 g/L) were mixed in a ratio 
of 1:1 in order to stop the otherwise ongoing reaction between pyruvate and 
lactate. The samples were immediately put on ice and transported to the 
laboratory in order to be measured directly after the test. Samples were analysed
batch-wise. For quantification of L-lactate in blood, enzymatic assays (Roche, Basel
Switzerland) with L-lactate dehydrogenase (L-LDH EC 1.1.1.27) were performed 22.
Lactate levels above the upper limit of normal (>1800 µmol/L) was referred to as
hyperlactataemia. Symptomatic hyperlactataemia was defined as a combination 
of hyperlactataemia with AEs.
Statistics
Group characteristics and serum levels were compared using the Wilcoxon test.
The Koziol test was used to compare serum levels that were measured more than
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In order to evaluate the ability of the OGTT to detect mitochondrial toxicity, we
determined the sensitivity and specificity when the upper limit of normal of 1800
µmol/L for the 60 minutes lactate level was used as cut-off value: higher levels
were assumed to be an indication for toxicity.
In addition, we calculated the area under the ROC curve (AUC) and we determined
the cut-off value for which the sum of the sensitivity and specificity was maximal. 
We used multiple logistic regression to evaluate the impact of other variables on
the result and to evaluate whether other variables or combinations of variables,
possibly in combination with lactate levels, would lead to a higher AUC. For this
purpose we carried out a stepwise model selection procedure with the variables
lactate level, age, BMI, disease duration, duration of therapy and type of therapy. 
Results
An OGTT was performed in 30 subjects. Measurement of haemoglobin, leukocytes,
platelets, creatinine and insulin before the OGTT did not show significant
differences between the two study groups (table 1). Mean time between AEs 
and the OGTT was 11 months (range 6-20). 
Serum levels
The mean baseline glucose levels were in the range between 4.9 and 6.2 mmol/L.
At t=60 min the glucose levels increased to mean levels of 8.6 mmol/L in the
group of patients with adverse effects and 8.5 mmol/L in group 1. At 120 min the
glucose levels declined again to baseline levels. 
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table 1   Characteristics of HIV-patients.
Group 1 Group 2
HIV-infected patients with HIV-infected patients with 
antiretroviral therapy antiretroviral therapy
without adverse effects with adverse effects related
to mitochondrial toxicity
Number 16 14
Gender 16 male / 0 female 11 male / 3 female
Mean age in years (range) 45 (40-52) 41 (27-52)
Mean duration of HIV in months 72 ± 19 92 ± 24
Mean CD4 per mm3 ± SD 424 ± 232 353 ± 275
Mean viral load copies/ml (range) 13.5 x 105 (<50-105) 3.0 x 104 (<50-105)
Mean duration of ART 51 (10-72) 66 (11-78)
in months (range)
Hemoglobin (mmol/L) ± SD 8.8 ± 0.8 8.5 ± 0.9
Leucocytes (x 109/L) ± SD 6.2 ± 1.9 6.0 ± 2.3
Platelets (x 109/L) ± SD 227 ± 74 231 ± 75
Creatinine (µmol/L) ± SD 93 ± 20 90 ± 16
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At baseline hyperlactataemia was only seen in three patients with AEs. The highest
lactate levels were found in the AEs group at all time points compared to the
group without AEs. An increase of lactate occurred in both groups at t=60 min. 
Lactate levels and adverse events
With 1800 µmol/L as cut-off for the 60 minutes lactate levels, the sensitivity was
57%: eight patients in group 2 had high levels (1900-2990 µmol/L). The specificity
was 81%: elevated lactates (>1800) were found in three patients in group 1 
(resp 1830, 2100 and 2160 µmol/L; 3/16 = 19%).
The area under the ROC curve was 0.75 and a cut off value of 1660 µmol/L lead 
to slightly better results: a sensitivity of 64% and a specificity of 81%.
No statistically significant relation between age, BMI, disease duration, and type
of therapy on the one hand and adverse events on the other hand was found.
Patients with adverse events, however, had longer duration of medication
(p=0.04). The combination of lactate level and treatment duration lead to an 
AUC of 0.80.
Patients with neuropathy had higher lactates during the OGTT than patients with
hepatic steatosis. This was reflected in the use of stavudine; 80% of patients 
with hyperlactataemia were on a stavudine although a statistically significant
difference could not be reached. 
Discussion
Our results demonstrate that an OGTT might be useful to detect (occult) hyper-
lactataemia as a result of mitochondrial impairment. At all time points mean 
L-lactate levels in the AEs group were higher compared to the other group, with
the highest value at t=60 min. One hour after glucose loading 8 (57%) of the
patients with AEs had hyperlactataemia (>1800 µmol/L) compared to 3 (19%) in
the group without AEs, corresponding to a sensitivity of 57% and a specificity of
81%. Althought the ROC analysis suggested 1660 µmol/L as a cut-off point, this did
not lead to higher specificity and the sensitivity only improved from 57% to 64%.
The combination of duration of medication gave an AUC of 0.80. 
Symptomatic hyperlactataemia with mitochondrial abnormalities in muscle biopsies
has been demonstrated by Gérard et al 18. They found an incidence of 0.8% per
year in HIV-infected adults on antiretroviral therapy, presenting with unexplained
clinical symptoms. Brew at all showed a significant correlation between serum
lactate and the development of nucleoside related neuropathy 6. At random
measurement of lactate in patients from our out-patient department revealed
overall higher lactate levels in patients suffering from ART-related neuropathy 41.
The question remains if symptomatic hyperlactataemia due to mitochondrial toxicity
affects only a minority of patients or might affect every individual in the long
term as a result of cumulative drug exposure 24;29. From our data we found that
the mean duration of antiretroviral therapy was longer in patients from group 2
(66 months) compared to patients from group 1 (51 months). 
Most patients with elevated lactate levels in both groups were on stavudine
(80%). Similar to our results, other studies found elevated lactate levels more 
68
Section Mitochondrial toxicity
proefschrift def  10-11-2008  14:56  Pagina 68
69
Chapter 4
table 2a   Treatment regimens of HIV-patients (group 1).
Group 1 Gender Age Medication
1 M 46 D4T + 3TC + NVP
2 M 49 AZT + 3TC + NVP
3 M 51 D4T + ddI 
4 M 48 D4T + 3TC + IDV + RTV
5 M 54 AZT + 3TC + NFV
6 M 44 D4T + 3TC + NVP
7 M 39 D4T + 3TC + IDV
8 M 42 AZT + 3TC + NVP
9 M 49 D4T + 3TC + NVP + LPV + RTV
10 M 37 D4T + 3TC + IDV + RTV
11 M 48 D4T + ddI + NVP
12 M 39 D4T + 3TC + NVP
13 M 42 AZT + 3TC + IDV
14 M 51 D4T + 3TC + IDV
15 M 43 D4T + 3TC + IDV + RTV
16 M 47 D4T + 3TC + NVP
table 2b   Treatment regimens of HIV-patients (group 2). 
Group 2 Gender Age Medication Adverse event Duration of AEs 
at time of OGTT (months)
1 M 48 D4T + 3TC + LPV + RTV neuropathy 10
2 M 49 D4T + ddI + IDV + RTV neuropathy 7
3 M 55 D4T + ddI + EFV neuropathy 7
4 M 37 D4T + 3TC + IDV + RTV neuropathy 20
5 M 38 D4T + 3TC + NVP neuropathy 8
6 M 27 D4T + ddI + SQV + RTV neuropathy 10
7 F 39 D4T + 3TC + NFV neuropathy 12
8 F 35 D4T + ddI + EFV neuropathy 16
9 M 41 D4T + 3TC + NVP neuropathy 11
10 M 46 D4T + ABC + APV neuropathy 14
11 M 32 D4T + 3TC + LPV + APV hepatic steatosis 9
12 M 47 AZT + 3TC + NVP hepatic steatosis 6
13 M 47 AZT + 3TC + SQV + RTV hepatic steatosis 14
14 F 43 AZT + 3TC + NFV hepatic steatosis 16
M = male, F = female
D4T = stavudine, 3TC = lamivudine, AZT = zidovudine, ddI = didanosine, ABC = abacavir, EFV = efavirenz,
NVP = nevirapine, LPV = lopinavir, APV = amprenavir, IDV = indinavir, RTV = ritonavir, SQV = saquinavir. 
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frequently in stavudine containing regimens 21;25;27;28;30;31;36;40;42. Routine lactate
measurement in patients on ART has not been recommended because low grade
stable hyperlactataemia or intermittent hyperlactataemia is of poor predictive
value for impending lactic acidosis 26;37. However, lactate measurement in 
combination with an OGTT can be used to detect NRTI-related toxicity in patients
suspected of mitochondrial related events, especially when lactate levels >2000
µmol/L are found. Although the sensitivity is not very high (around 50%), the
specificity is 80% for lactates >1800 µmol/L and reaching 90% specificity for 
levels >2000 µmol/L. Future tests have to be performed in order to improve 
the diagnositic value of the test. 
Elevated L-lactate levels can also occur in liver and kidney failure due to impaired
clearance by these organs 17;32. Looking at our population with elevated L-lactate
levels after glucose loading, only 2 patients had elevated transaminases without
impairment of liver function. No other causes could be identified that might have
induced the transaminase levels except the antiretroviral drugs. There were no
patients with hepatitis B or C co-infection and none of the patients had impaired
kidney function 1. 
An OGTT with measurement of lactate one hour after glucose loading can be 
used as additional test in patients with suspected drug-induced mitochondrial
impairment to detect (occult) hyperlactataemia. Based on our study and literature
we would not recommend measurement of lactate more then one hour after 
glucose loading. Lactate levels >1800 µmol/L during the OGTT were associated with
antiretroviral therapy related AEs. We suggest performing an OGTT as an additional
test in patients with symptoms suspect for AEs to discern NRTI-related mitochon-
drial toxicity. Depending on the severity of symptoms and the possibility to start
other drugs, antiretroviral therapy should be switched in patients with toxicity.
Additional data will be necessary to evaluate the clinical importance 
of an OGTT as early predictor for the development of side effects. 
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Abstract
Protease inhibitors are known to interfere with lipid and glucose metabolism
resulting in among others insulin resistance with hyperglycaemia, hyper-
triglyceridaemia and elevated total and LDL-cholesterol. In this study we 
investigated metabolic effects in antiretroviral therapy-naive HIV-patients. 
This was a substudy of a prospective clinical trial of HIV antiretroviral 
therapy-naive patients who started on a regimen of AZT/3TC and LPV/RTV and
were randomised to either continuation or switch to AZT/3TC/ABC at week 24.
Prospectively we measured plasma lipids, apolipoproteins, glucose, insulin, 
leptin and hsCRP concentrations from baseline to week 72 in 21 treatment-naive
HIV-seropositive patients. 
In the first 24 weeks after start of LPV/RTV treatment there was an increase 
of serum lipids: total cholesterol 25%, LDL and VLDL-cholesterol 16% and 43%
respectively, triglycerides 32% and VLDL triglycerides 40% and lp(a) 36%. The
lipid values stabilised after week 24 in the LPV/RTV users and decreased to 
baseline levels in the group that switched to AZT/3TC/ABC; decrease in total 
cholesterol of 15% (p<0.001), in LDL-cholesterol 13% (p=0.03) and 31% decrease
in triglycerides (p=0.003). 
Antiretroviral therapy with LPV/RTV is associated with an atherogenic lipoprotein
profile. Switch to AZT/3TC/ABC induced recovery of these atherogenic changes.
Antiretroviral treatment with AZT/3TC/ABC has no negative metabolic effects.
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Introduction
The metabolic syndrome consisting of impaired glucose tolerance, insulin 
resistance and dyslipidaemia is considered as one of the most important side
effects of antiretroviral therapy (ART) in HIV-infection 1;2. The pattern of
dyslipidaemia is especially seen in patients on protease inhibitors (PIs) and is 
characterised by elevation in total and low density lipoprotein (LDL) cholesterol 
and triglycerides, together with a decrease in high density lipoprotein (HDL) 
cholesterol 3-6. This lipid profile is known as the atherogenic lipoprotein profile
which is associated with increased cardiovascular risk 7;8. In contrast to PIs, the
non nucleoside reverse transcriptase inhibitors (NNRTIs) nevirapine and efavirenz
have a positive effect on HDL-cholesterol 9-11. In general NNRTIs are associated with
a more favourable lipid profile than the PIs. Of the PIs nelfinavir has the most
favourable lipid profile 12. 
Incidence rates vary but up to 40% of HIV-infected patients on ART may experience
dyslipidaemia 13-15. Hypercholesterolaemia and hypertriglyceridaemia after lopinavir
and ritonavir use was found to occur in 17% and 40% respectively 16. Elevated
triglycerides presented in small very low density lipoprotein (VLDL) particles 
are also considered to be atherogenic, although it is not clear if this is the 
predominant form of VLDL in HIV-patients. Next to antiretrovirals, genetic factors
such as apolipoprotein C (apoC) and apolipoprotein E (apoE) variants play a role 
in ART-associated dyslipidaemia 17-20.
The pathogenesis of insulin resistance is complex, including direct effects of
antiretroviral medication (particularly PIs) on glucose uptake and indirect effects 
of dyslipidaemia, inflammation and body composition. Laboratory parameters
that have been studied in this process are leptin and high sensitive C-reactive
protein (hs-CRP) 21;22. Until now, extensive measurement of these cardiovascular-
related metabolic parameters has not been combined in a prospective trial 
comparing a PI-containing regimen versus switch to a non-PI-containing 
regimen.
Since HIV-patients have to endure long term ART, reduction of side effects is very
welcome. Ritonavir-boosted lopinavir (LPV/RTV) is a very potent PI combination, 
but due to the relative unfavourable metabolic side effects, its use in the last years
has been changed from first to second line treatment, at least in most of the 
Dutch centres for the treatment of HIV-infection. The FREE study is a randomised
controlled trial with the aim to explore whether the metabolic side effects of
LPV/RTV could be avoided if it is replaced by a triple nucleoside regimen. In this
trial all patients started with zidovudine and lamivudine (given as the combination
drug combivir®; AZT/3TC) and LPV/RTV (given as the combination drug kaletra®),
When the viral load was below 50 copies/ml between week 12 and week 24 after
start of treatment, the patients were randomised to continuation of this regimen or
to the combination drug trizivir® (AZT/3TC/ABC), which contains 3 nucleoside reverse
transcriptase inhibitors (NRTIs); abacavir 300 mg (ABC), zidovudine 300mg (AZT) and
lamivudine 150 mg (3TC) b.i.d. 
We report the results of a substudy of this clinical trial in which we determined
several biochemical parameters of glucose and lipid metabolism and inflammation. 
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Methods
Study design
The FREE study (ClinicalTrials.gov NCT00405925) is a prospective, multi centre
cohort. Two centres joined this substudy: UMC st Radboud Nijmegen and Rijnstate
hospital Arnhem. 
Inclusion criteria for the FREE study were: male or females older than 18 years,
able and willing to sign informed consent, CD4 count ≤350/mm3 and HIV-1 RNA
≥30.000 copies/ml. The following metabolic parameters were required for 
inclusion: fasting glucose ≤7 mmol/L (non-fasting <11 mmol/L), fasting 
triglycerides ≤2 mmol/L and LDL-cholesterol ≤4 mmol/L or LDL/HDL ratio 
≤4.1. Patients were excluded if metabolic parameters were not within the 
range requested in the inclusion.
Initially 28 patients were screened. A total of 21 patients started antiretroviral
therapy between March 2003 and January 2006 and were consecutively observed
up to week 72. 
Follow-up visits were carried out at fixed time points: at baseline, and week 12,
24, 48 and 72. Venous blood samples were drawn for the measurement of the 
following metabolic parameters: total cholesterol, LDL-cholesterol, HDL-cholesterol,
VLDL-cholesterol, triglycerides, VLDL-triglycerides, lipoprotein (a) (Lp(a)), 
apolipoprotein B (apoB), fasting glucose, fasting insulin, oxidised LDL (oxLDL),
serum autoantibodies against oxLDL (ab oxLDL), High sensitive CRP (hsCRP) and
leptine. ApoE phenotyping was only investigated at baseline. 
Laboratory measurements
Venous blood was drawn by venipuncture after an overnight fast. Plasma total
cholesterol and triglycerides concentrations were determined using commercially
available enzymatic reagents (Hitachi 747, Roche, Almere, The Netherlands). 
VLDL-cholesterol was isolated from whole plasma by ultracentrifugation at density
(d) = 1.006 g ml-1 for 16 h at 36,000 rpm in a fixed angle rotor (TFT 45.6 rotor,
Kontron), in a Beckman L7-55 ultracentrifuge. HDL-cholesterol was determined 
by the polyethylene glycol 6000 method 23. LDL-cholesterol was calculated by
subtraction of VLDL-cholesterol and HDL-cholesterol from plasma triglycerides.
Enzymatic, commercially available reagents (Roche Molecular Biochemicals,
Germany, catalog no. 237574 and Sera Pak, Miles, Belgium, catalog no. 6639,
respectively) determined cholesterol and triglycerides. Total plasma apoB 
concentration was determined by immunonephelometry 24. Both hsCRP 
(Imtec Immun-diagnostica, Berlin, Germany) and plasma oxLDL (Mercodia,
Uppsala, Sweden) were determined by ELISA. Plasma glucose was determined 
by a commercially available glucose oxidation method (GOD-PAP, Hitachi 747; 
Roche Molecular Biochemicals, Indianapolis, IN). Plasma insulin concentrations
were assessed by means of radioimmunoassay (in-house RIA [interassay
coefficient of variation (CV), 10.3%]) 25. Insulin resistance was assessed by the
homeostasis model assessment (HOMA). The HOMA-index was calculated from 
the fasting concentrations of insulin and glucose using the following formula:
HOMA-index = fasting serum insulin (mU l-1) x fasting plasma glucose 
(mmol l-1)/22.5 26. 
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Statistics
In order to remove the skewness in the laboratory data, we first applied a 
logarithmic transformation. The transformed variables were then analyzed using 
a mixed linear model with random factor patient and fixed factors time and
treatment. We calculated 95% confidence intervals (CI) on the logarithmic 
scale and we transformed these back into percentages for interpretation. 
Ethics
The research protocol was approved by the regional Medical Ethic Committee
Arnhem-Nijmegen and written informed consent was obtained from all subjects. 
Results
A total of 28 patients were initially screened for this study and 21 were consecutively
observed up to week 72. In 3 patients only baseline data were available, they did
not meet the criteria for the main (FREE) study and in 4 patients we could only
collect data till week 24. 
During the study period five patients presented with adverse events classified as
grade 2 hypercholesterolaemia (>6.2 mmol/L; WHO toxicity scale) whereas no
patients experienced grade 2 hypertriglyceridaemia (>4.5 mmol/L). 
81
Chapter 5
table 1   Patients’ characteristics.
AZT/3TC+LPV/RTV AZT/3TC+ABC
Number of patients enrolled 16 12
Sex (%) 15 males 8 males 
1 female 4 females 
Race (%) 11 Caucasian 9 Caucasian
3 Black 2 Black
2 Asian 1 Asian 
Only baseline data 3
Data till week 24 4
Data till week 72 9 12
Number of eligible patients 9 12
CDC classification A 5 10
CDC classification B 3 2
CDC classification C 1 0
Mean HIV-RNA level (log copies/mL) 5.92 5.35 
CD4 cell count (cells/mm3) ± SD 183 ± 124 161 ± 87
BMI (kg/m2) ± SD 22 ± 4 23 ± 3
Age (years) ± SD 42 ± 10 39 ± 10
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Baseline values are depicted in table 1. In the first weeks (mostly 24) till randomisation
total cholesterol increased with 25% (CI 14%-37%, P<0.0001) due to increase in 
LDL-cholesterol (16%) and VLDL-cholesterol (43%) and HDL-cholesterol (33%). The
mean total cholesterol at baseline was 4.39 mmol/L and increased to 5.49 mmol/L
(range 2.47-6.50 mmol/L). Triglycerides increased with 32% due to increase in VLDL
triglycerides (40%). Mean triglycerides changed from 1.57 mmol/L at baseline (range
0.78-2.91) to a mean value of 2.07 mmol/L at randomisation (range 1.01-4.10
mmol/L). Increase of 36% was seen in lp(a). ApoB increased (17%) due to increase 
in LDL and VLDL particles. Overall patients with low baseline levels had a slightly
larger increase in lipids compared to patients with rather high baseline levels
although the difference was not statistically significant. 
No effect on glucose (2% increase), insulin and HOMA-score (both 11% decrease) was
found. This was also true for LDL/HDL ratio. No effect of LPV/RTV and AZT/3TC/ABC was
found on the inflammatory parameters oxLDL and ab ox LDL.
Leptin increased with 26% and no correlation was found with body mass index (BMI).
HsCRP decreased significantly with 45% (CI 12-66%). However, after six months
hsCRP stabilised and no differences between the two treatment arms were observed. 
After the randomisation to either continuation with AZT/3TC + LPV/RTV or switch to
AZT/3TC/ABC, several differences in the metabolic parameters between both treatment
arms were found. The total cholesterol levels in the AZT/3TC/ABC arm were 15% lower
(CI 9-20%) than in the group continuing LPV/RTV. The same pattern was seen for the
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table 2   Laboratory parameters at baseline, at randomisation and at week 72 and differences
in metabolic parameters after switch to AZT/3TC/ABC. 
(Group A = Week 72 AZT/3TC +LPV/RTV group, Group B = Week 72 AZT/3TC/ABC group)
Parameter Baseline Rs Change Baseline-Rs Group Group Differences after switch
A B to Group B compared to
Group A
Total chol (mmol/L) 4.39 5.49 25% (p<0.001) 5.39 4.67 -15% (p<0.001)
LDL-chol (mmol/L) 2.87 3.33 16% (p=0.02) 3.20 2.90 -13% (p=0.03)
HDL-chol (mmol/L) 0.94 0.97 33% (p<0.001) 1.28 0.99 2% (p=0.62)
VLDL-chol (mmol/L) 0.53 1.39 43% (p=0.06) 0.91 0.97 -30% (p=0.12)
TG (mmol/L) 1.57 2.07 32% (p=0.009) 2.19 1.42 -31% (p=0.002)
VLDL-TG (mmol/L) 0.99 1.39 40% (p=0.05) 1.63 1.28 -8% (p=0.70)
Lp(a) (mg/L) 400 544 36% (p<0.001) 643 533 -2% (p=0.84)
ApoB (mg/L) 891 1042 17% (p<0.001) 1068 916 -12% (p=0.008)
Glucose (mmol/L) 4.8 4.9 2% (p=0.36) 5.3 4.9 0% (p=0.91)
Insuline (mU/ml) 10.0 8.9 -11% (p=0.31) 9.9 10.5 18% (p=0.43)
oxLDL (U/L) 72 78 8% (p=0.28) 76 73 -6% (p=0.27)
hsCRP (mg/L) 3.9 2.15 -45% (p=0.01) 1.20 3.70 72% (p=0.18)
Leptine (ng/ml) 9.3 11.9 26% (p=0.05) 6.0 14.0 18% (p=0.24)
HOMA-index 2.1 1.9 -11% (p=0.33) 2.4 2.0 4% (p=0.86)
Rs = randomisation, TG = triglycerides, chol = cholesterol.
At baseline and randomisation all patients are on AZT/3TC+LPV/RTV.
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other serum lipids and lipoproteins; apoB, LDL and VLDL-cholesterol, triglycerides
(12%, 13%, 30% and 31% lower respectively). The major difference after switching to
AZT/3TC/ABC was a decrease of 31% in triglycerides (CI 13-45%, p=0.002). In the group
that continued LPV/RTV treatment, the increase in lipid values stabilised after six
months in contrast to the AZT/3TC/ABC group where total cholesterol and triglycerides
returned mostly to baseline values. No differences in glucose and insulin were
found. (table 2, figure 1 and 2). Moreover, the other parameters did not change
after 24 weeks of treatment with LPV/RTV. Changes in metabolic parameters were not
related to age, sex, baseline CD4 or HIV-RNA.
The baseline ratio of apoCII/CIII was normal in all patients. The apoE phenotyping
results were as follows: apoE 3/2 was found in 7 patients, apoE 3/3 in 6 patients,
apoE 4/2 1 patient, apoE 4/3 in 4 patients and apoE 4/4/ in 1 patient (data of 2
patients concerning apoE phenotyping were missing). There was no relation
between the ApoE phenotyping and (changes in) serum lipids.
Discussion
We demonstrated that LPV/RTV is associated with the development of an atherogenic
lipid and lipoprotein profile with exception of the rise in HDL-cholesterol. Switch to
AZT/3TC/ABC can reverse the atherogenic lipid profile as lipid and lipoprotein levels
decreased to baseline values. 
Antiretroviral therapy with AZT/3TC/ABC decreased triglycerides, VLDL and LDL-cholesterol.
No change in glucose was seen. 
PIs are known to interfere with lipid and glucose metabolism resulting in, among
others, insulin resistance with hyperglycaemia, hypertriglyceridaemia and elevated
total and LDL-cholesterol. Like other investigators we found that already shortly
after the start of antiretroviral drug use changes in metabolism of lipids and glucose
can be observed 14-16. Within 24 weeks of treatment with LPV/RTV and 2 NRTIs a rise
in total cholesterol, LDL-cholesterol, VLDL-cholesterol, triglycerides, VLDL-triglycerides
lp(a), and apoB was observed. After week 24 the increased serum lipids stabilised in
those who continued LPV/RTV use. This was in contrast to the patients that were
randomised to AZT/3TC/ABC , in whom serum lipids decreased mostly to baseline levels.
The present data suggest that lipid increase will reach its maximum between 24-48
weeks. A retrospective analysis of HIV-infected patients on LPV/RTV also revealed
increase of total cholesterol and triglycerides early after introduction of LPV which
remained subsequently stable for a period of 15 months 15. 
Deficiency of the adipocyte hormone leptin is associated with insulin resistance and
hypertriglyceridaemia 27. It is suggested that initiation with PIs may lead to leptin
deficiency 28, however we found the opposite i.e. an increase in leptin in patients
on lopinavir. Obese patients might have increased leptin levels due to leptin 
resistance. However this would not be the case in our study since the body mass
index (BMI) of our population was within the normal range. Recently investigations
in HIV-infected children also did not demonstrate any difference in serum leptin in
patients on PIs or on non-PI ART or therapy-naive patients 29. Furthermore, we did
found no difference between leptin levels in lopinavir and AZT/3TC/ABC users,
although our study population was rather small.
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Increased baseline levels of serum cholesterol and triglycerides have been associated
with a higher risk of developing clinically significant hyperlipidaemia 16. This was
not found in our study, however this might be due to the strict inclusion criteria for
lipids in this study. There was even a tendency that patients with low baseline levels
had a larger increase in lipids even more than patients with rather high baseline
levels, although this was not statistically significant. 
Apo lipoproteins are known to be the best markers to predict cardiovascular heart
disease. Our data show an initial increase in apoB during the first 24 weeks of LPV
treatment, which stabilised in the next months and decreased when patients were
switched to a PI-free regimen. In a recent published report no difference between
apoB levels was found between HIV-infected patients on ART and healthy age- and
gender matched controls 30. Variants of ApoE genotypes have been associated with
severity of ART-induced dyslipidaemia and with lipodystrophy induction. The ApoE2
genotype associated with increased triglycerides was not found in our patients.
Additionally, apoC3 increases the risk of fat redistribution 14;31. If more insight is
gained in the genetic pathogenesis of ART-induced dyslipidaemia, pharmacogenomic
stratification might be helpful to prevent serious lipid problems in HIV-patients
starting with HAART.
The risk for cardiovascular disease in HIV is known to be multifactorial and includes,
stage of HIV-infection, ART, nutritional status, exercise and genetic parameters 32;33.
A multifactorial origin of dyslipidaemia is also suggested by the fact that the degree
of hyperlipidaemia varies widely. Furthermore, higher lipids are observed in
patients with the lipodystrophy syndrome 34. HIV affects the physiology of the
endothelium. Endothelial dysfunction and or injury have been seen in young 
HIV-patients without cardiovascular risk factors in autopsy studies 35. Hypo-alpha-
lipoproteinaemia is not only hypothesised to be drug-related but also secondary to
HIV-infection itself 36. Additionally, advanced stage HIV-infection is associated with
an atherogenic lipid profile including a high prevalence of small density LDL (sdLDL),
which can be reflected by apoB 37. It is still remarkable that patients switching from
PI to AZT/3TC/ABC showed a significant amelioration of serum lipids. Even average
increase of 28% total cholesterol and 96% triglycerides compared to pre-treatment
values have been published in large series of PI-naive HIV-patients 38. The DAD
study reported an increased risk of myocardial infarction in patients exposed to
abacavir and didanosine within the preceding 6 months 39. This risk disappeared 
6 months after drug cessation. There were no cardial events during our study.
Insulin resistance with impaired glucose tolerance (without frank diabetes) may
also be associated with HIV-infection itself as this phenomenon is also observed
in patients not receiving PI therapy, perhaps resulting from the direct effect of
the virus on pancreatic beta cell function and insulin secretion 40.
In a large cohort of HIV-infected subjects the 10-year predicted risk of developing
coronary heart disease was estimated. Overall, 17% of males and 12% of females
met criteria for high predicted cardiovascular heart disease risk 41. The predicted
rate of vascular events was higher for treated HIV-infected patients compared to
untreated HIV-patients. Earlier studies also showed these risks. In one cohort of
HIV-patients, ART was associated with a 27% relative increase in the rate of
myocardial infarction per year of exposure over the first 7 year of use 7. 
Recently, in a large cohort of women lower HDL-cholesterol and higher 
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triglyceride levels were observed in HIV-infected women who used PIs or 
untreated patients with HIV-infection compared to HIV-negative controls 42. In
addition, LDL-cholesterol levels were higher in the PI users than in the untreated
HIV-positive women, but the latter had lower LDL-cholesterol levels compared to
HIV-negative women. Lamivudine, didanosine, nevirapine and efavirenz were
independently associated with higher HDL-cholesterol levels. Ritonavir,
indinavir/ritonavir and nelfinavir were associated with higher LDL-cholesterol 
levels. Stavudine, abacavir and all ritonavir-containing regimens were associated
with higher triglyceride levels. Tenofovir was associated with lower triglycerides. 
There are only a few prospective studies in homogenous patient populations that
have examined the usefulness of serum lipid measurement in the treatment
of HIV-infection. More prospective data are necessary to evaluate the clinical
importance of metabolic evaluation as an early predictor for the development
of side effects and its risk for cardiovascular disease in the future. 
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Abstract
This study was to determine the correlation between plasma stavudine 
concentrations and lipoatrophy (LA), one of the major adverse events in 
patients on stavudine and one of the major reasons to discontinue stavudine. 
Plasma drug concentrations were retrospectively analysed in patients who 
were on a stavudine-containing regimen for at least 12 months. We defined 
two groups of patients: 21 patients with LA and 15 patients without LA or other
stavudine-related side effects (i.e. neuropathy). 
We analysed stavudine concentrations in 212 plasma samples; 87 in the control
group and 125 in the LA group, with a mean of 4 plasma samples per person 
at least 2 a year). Demographics were comparable in LA patients and controls,
except the duration of stavudine use which was longer in the LA group: 55 versus
42 months in the control group. Overall LA patients had higher drug exposure 
to stavudine compared to the controls, this was seen in the geometric 
concentration ratios (CR) respectively 0.978 and 0.741 (p=0.04) and also a higher
percentage of CR values >1.0, representing a drug concentration above the 
normal population curve (46% versus 23%, p=0.02). In addition, the duration 
of stavudine therapy was independently associated with lipoatrophy (p=0.05). 
In the multivariate analysis both duration of stavudine (p=0.05) and CR >1.0
(p=0.02) were independently correlated with LA.
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Introduction
Thymidin nucleoside reverse transcriptase inhibitors (tNRTIs) containing regimens
have been associated with various adverse events such as lipoatrophy, peripheral
polyneuropathy and lactic acidosis. These adverse events seem to be class specific;
eventhough the pathophysiology is not yet fully elucidated. Especially the 
development of lipoatrophy is one of the major concerns for patients and 
physicians when choosing drugs for a first line antiretroviral regimen. Several
prospective studies have shown that the use of stavudine and to a lesser extend
zidovudine are major contributors in the development of lipoatrophy. Stavudine 
is therefore no longer recommended by the international guidelines for first line
treatment of previously antiretroviral naive patients in North America and Europe.
However, a substantial amount of HIV-patients in countries with limited resources
use stavudine 1. For instance, in Uganda and Kenia a cohort of respectively 1073
and 284 patients were treated with antiretroviral therapy containing stavudine.
Another report from South Africa analysed toxicity in 1700 patients receiving 
antiretroviral therapy, consisting of either stavudine or zidovudine 2-7.
Several trials in HIV-treated subjects have showed evidence that side effects are
dependent on plasma drug concentrations 8-12. There is conflicting data about the
best representative of NRTI levels; intracellular or plasma 13. To assess the clinical
use of plasma stavudine concentrations and its relation with the development of
toxicity, we performed a study regarding plasma stavudine levels in relation to
lipoatrophy (LA). A major impediment for the success of HIV treatment is poor
adherence, which is often a result of side effects. In this respect lipoatrophy is the
most feared event by the patient. With this in mind, we wanted to investigate the
relationship between stavudine plasma levels and lipoatrophy appearance. 
The purpose of this study was to verify whether the side effect lipoatrophy, which
often occurs after at least several months of therapy, could be related to elevated
plasma concentrations of stavudine. In this way drug monitoring can be helpful in
the decision making of changing a probable toxic antiretroviral regimen to a less
toxic regimen which can be continued for a prolonged time, resulting in chronic
suppression of HIV-infection. 
Patients and methods
Study design
Plasma concentrations are routinely measured in all HIV-patients on antiretroviral
therapy visiting our outpatient department. We analysed data of all patients that
used or had used stavudine in the period 1996-2006. We analysed our database
to find all patients on a stavudine-containing regimen. All patients had to be on
their first antiretroviral therapy regimen. From our database we selected 106
patients with a stavudine-containing regimen. Patients were divided into two
groups based on the development of adverse events (AEs) due to stavudine.
Patients that used or had used stavudine without experiencing AEs were enrolled
in group 1 (32 controls). Patients that experienced lipoatrophy due to stavudine
were enrolled in group 2 (49 LA patients). Patients with other AEs due to stavudine
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were not enrolled. Because body shape changes with fat accumulation 
(lipohypertrophy) have been largely associated with protease inhibitors, we
excluded patients who experienced only lipohypertrophy 14;15.
Because lipoatrophy mostly occurs after at least several months of therapy, 
we decided to enrol only patients that used or had used stavudine for at least 12
months 6-18. After correction for duration of therapy 36 patients were left from 
the initially selected 81 patients on a stavudine-containing regimen (figure 1). 
Of all the patients meeting the criteria we retrospectively measured 2 samples 
a year with an interval of at least 4 months between the samples.
Lipoatrophy was defined as peripheral fat loss (face, buttocks and extremities) 
and lipohypertrophy as central fat accumulation (abdominal, neck and breasts)
both reported by the patient and confirmed by physical examination (i.e. waist
to hip ratio measurements, lipodystrophy scoring system) 19;20. Patients, who 
were clinically suspected of severe abdominal fat accumulation, had indeed
increased intra-abdominal fat tissue (evaluated by DEXA or CT scan).
Concentration Ratio (CR)
A concentration ratio (CR) was calculated for every plasma sample, comparing 
the stavudine plasma level of the patient with time-adjusted stavudine plasma
concentration for the population. Based on multiple measurements over time, 
for every individual the geometric mean value of the stavudine CR value was 
calculated. In addition we looked at CR levels >1.0, which represent higher 
exposure when compared to the overall population 21. For a normal distribution
we used the geometric mean CR. 
Drug monitoring 
Stavudine plasma concentrations were determined by a high-performance liquid
chromatography (HPLC) assay as previously reported 22. The volume of the plasma
sample was 500 microL. The lower limit of quantification is 0.015 mg/L. Average
accuracy ranged from 98-101% and precision ranged from 1.3-2.2%. 
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figure 1   Flow diagram: Inclusion of patients.
106 patients on stavudine
32 patients with 49 patients with 25 patients with other
no AEs lipoatrophy stavudine related AEs
Group 1 Group 2
15 controls using stavudine 21 patients with lipoatrophy
without AEs ≥12 months using stavudine ≥12 months
87 plasma samples 125 plasma samples




Statistical evaluation was performed with SPSS for windows, version 11.0.
Geometric means with 95% confidence intervals were calculated for all 
samples in each individual. For the analysis, a p-value of ≤0.05 was regarded 
as significant. We performed a logistic multiple regression analysis with 
lipoatrophy (present or not present) as the outcome variable versus demographic
factors, co-medication in HAART (except NRTI because this was lamivudine in 
the majority of the patients) and CRs. In addition, the variable duration of
treatment was analysed as an independently factor for lipoatrophy. 
Ethics
All our HIV-infected outpatients are asked for informed consent to use their
demographic data in an anonymous database. Maintenance of our database 
and its use for retrospective analysis of patient’s outcomes are approved by
the ethics committee.
table 1   Patients’ characteristics.
Controls Lipoatrophy
Number of patients 15 21
Sex (%) 10 males (67) 15 males (71)
5 females (33) 6 females (29)
Race (%) 9 Caucasian (60) 18 Caucasian (86)
4 Black (27) 2 Black (10)
1 Asian (7) 1 Asian (5)
1 Hispanic (7)
Number of samples 87 125
Mean number of samples per person (range) 4.3 (2-10) 4.6 (2-9)
Mean HIV-RNA level (log copies/mL) 4.63 ± 0.93 4.63 ± 0.90
at start stavudine ± SD
CD4 cell count at initiation of stavudine 210 ± 125 205 ± 128
(cells/mm3) ± SD
Weight (kg) ± SD (range) 68 ± 10 (52-82) 70 ± 10 (48-85)
Mean age (years) at start stavudine (range) 40 (23-57) 39 (25-58)
Duration of stavudine in months ± SD (range) 42 ± 21 (15-86) 55 ± 18 (30-84)
Mean stavudine concentration (mg/L) ± SD 0.174 ± 0.102 0.270 ± 0.172
Mean CR ± SD 0.799 ± 0.309 1.126 ± 0.514
Median CR ± SD 0.833 ± 0.414 0.952 ± 0.288
Geometric mean ± SD 0.741 ± 0.295 0.978 ± 0.348
% CR >1.0 ± SD 23 ± 27 46 ± 29




Retrospectively we analysed plasma samples in 36 patients using stavudine.
Plasma stavudine concentrations were measured in 15 controls (10 males and 5
females) and 21 lipoatrophy patients (15 males and 6 females). A total of 212 
samples were analysed: 87 in the control group and 125 in the LA group. The 
range of samples per patients varied from 2 to 10 with a mean of 4 samples per
individual in both groups. The mean age at the start of stavudine was 40 and 39
years in the control and LA group, respectively. There was an equal percentage of
females between the two groups (33% in controls and 29% in LA patients). In
both groups the majority of patients were Caucasian, 60% and 86% in the control
and LA group, respectively. In the control group there were 4 Black patients (27%),
1 Asian (7%) and 1 Hispanic patient (7%). Furthermore, the LA group consisted of


















Control group LA group
figure 2   Geometric means of CR in patients with lipoatrophy and controls.
In both groups, there was one value far above the other geometric means, which did not lead to 
statistical significant differences. The median values are marked in the box-plots. 
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initiation of stavudine was 210 and 205 cells/mm3 in the control group and LA
group, respectively (p=0.84). In the control group 10 out of 15 patients were on 
a NNRTI containing regimen and the other 5 used a PI versus 10 out of 21 patients
using a NNRTI and 11 patients using a PI in the LA group (p=0.33). The concomittant
medication consisted in both groups of lamivudine (only one patient in every
group was on didanosine). Except for duration of therapy, which was longer in 
the LA group, there were no statistically significant differences in patient
characteristics between the groups. The duration of stavudine in the LA group 
was 55 months (range 30-84) in the LA group and 42 months (range 15-86) in the
control group. The dosage of stavudine was 40 mg twice daily, only one patient
in each group used 30 mg twice daily due to low bodyweight (<60 kg).
The overall drug exposure to stavudine expressed in the geometric mean values
was higher in the LA group compared to the controls, respectively 0.978 and 0.741 
(p=0.04, figure 2). In both groups there was one value far above the other 
geometric means (figure 2), which did not lead to statistical significant
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figure 3   Percentage of CR >1 in patients with lipoatrophy and controls.
The median values are marked in the box-plots. 
proefschrift def  10-11-2008  14:57  Pagina 99
differences. In addition, CR values >1.0, representing a drug concentration above
the normal population curve, were more often seen in the LA group than in the
controls (46% versus 23%, p=0.02, figure 3). Table 1 provides an overview of the
results. 
In the multivariate regression analysis duration of stavudine therapy (p=0.05) 
and CR level >1.0 (p=0.02) were both independently associated with lipoatrophy. 
No association between body weight and stavudine levels were found.
Discussion
Since clinicians and patients are often confronted with side effects, we wanted to
evaluate drug exposure in patients on antiretroviral therapy. Our analysis showed
higher plasma stavudine levels in patients with LA compared to the patients 
without adverse events. Besides, these patients had more often a CR >1.0, 
representing a drug concentration above the normal population curve. Yet, 
no such analysis concerning NRTIs has been reported. Our results confirm earlier 
data reporting longer duration of stavudine use in patients experiencing 
lipoatrophy, but we show that high exposure to stavudine is an independent
predictive factor 16-18. 
Untill now TDM has been successfully applied to NNRTIs and PIs and to a lesser
extend for NRTIs. Efficacy of NRTIs has not been correlated to plasma drug levels
because these drugs must be converted to active intracellular metabolites to
become active. Intracellular concentrations of NRTI-triphosphate compounds have
been related to plasma HIV-RNA levels and CD4 cell counts 23. There is only limited
experience with the use of NRTI drug monitoring. There are two studies by
Fletcher et al. that investigated concentration-controlled NRTI management in
zidovudine and lamivudine therapy. They especially compared antiviral response
in fixed-dose regimens versus concentration-controlled regimens, however the
trials did not assess NRTI-associated toxicity in relation to plasma levels 13;24. 
For dose-related AEs, patients who experience adverse events are hypothesised 
to be those with higher plasma concentrations. Possible reasons for this 
phenomenon might be greater absorption, slower metabolism, change in 
drug transporters or reduced body weight and thereby a small volume of
distribution 25-28. For example, Gatti et al discovered a clear relationship between
ritonavir plasma concentrations and side effects 8. In addition, Dieleman et al
found elevated indinavir plasma concentrations in patients with cristalluria 9.
Recently, a correlation was found between neuropsychiatric adverse events and
efavirenz plasma levels in HIV-patients receiving long-term therapy with 
efavirenz 12. Patients with higher efavirenz plasma levels were at risk for central
nervous system toxicity. Additionally, increased bilirubin levels are associated 
with elevated concentrations of lopinavir, indinavir and atazanavir 10;11.
Our data provide interesting insights into possible uses for TDM and/or lower 
doses of stavudine. Our data suggest that the occurrence of LA can be predicted 
by higher plasma drug concentrations of stavudine. In this way tolerance of
antiretrovirals can be improved by avoiding excessive plasma concentrations. 
By monitoring drug levels of stavudine or starting with a lower dose of stavudine,
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toxicity can be found in an early phase when irreversible damage still could 
be prevented. A lower dose of stavudine with or without drug monitoring may
contribute to the safe use of stavudine in therapy-naive and NRTI-experienced
patients that need this antiretroviral drug. Eventually, stavudine plasma 
monitoring can be applied in stavudine-naive patients to prevent LA by adapting
the stavudine dose in case the CR exceeds the normal level of 1.0. In the same
way, stavudine can be applied in patients experiencing AEs from other NRTIs. Few
studies looked at the use of lower dose of stavudine to reduce side effects 29-31
Under strict control of viral load it was possible to reduce stavudine dosage 
resulting in less side effects compared to standard dose regimens. Recently, an
interesting study investigated the role of lowering stavudine dose or switching 
to tenofovir compared with standard stavudine dose in patients on long-term
stavudine therapy 32. Lowering stavudine dose was associated with improvement
of lipoatrophy. No virological failures were reported in both groups. However,
none of these studies looked at plasma stavudine concentrations. Combining
these data and our results we suggest that reduction to a twice-daily dose of
30 mg stavudine might be safer and even effective in a majority of patients. 
In addition, we suggest that a plasma stavudine concentration ratio (CR) <1.0 
(for example 0.8-1.0) might be a safe level for treatment of HIV-patients to 
prevent lipoatrophy. Although the above mentioned studies described efficacious
control of HIV, detailed studies have to be performed to prove this hypothesis.
Interesting, a recent addendum to the WHO guidelines on antiretroviral therapy
for HIV-infection in adults and adolescents recommends now a lower dosage for
stavudine (30 mg twice daily).
Due to genetic and environmental factors, there is a wide inter-patient variability
when measuring drug exposure to a standard dose. Earlier studies have proven 
a relationship between drug exposure and efficacy or toxicity 9;26;33-37. This 
inter-individual variability makes drug monitoring useful in these specific 
situations to predict not only virological response but also toxicity. Because 
symptoms are not always present or appear only until an irreversible phase 
has been reached, timely identification of toxicity is essential for the optimal
treatment of HIV-patients.
Although it is frequently stated that plasma concentrations do not correlate 
with intracellular active NRTI-triphosphate metabolites, our data show that
plasma NRTI concentrations give a good reflection of toxicity 23;35;38. Therefore,
high plasma drug levels of stavudine are probably a useful reflection of its 
intracellular concentrations. Till now less attention has been paid to the 
monitoring of plasma concentrations of NRTIs in contrast to PIs and NNRTIs. In 
the absence of easier techniques for measuring NRTI in drug monitoring, plasma
NRTI levels can be well used as a replacement of intracellular measurement. 
It has not clearly been elucidated which factors additionally might have played 
a role in the elevated plasma drug levels in the LA group. Enhanced plasma 
concentrations may have a multifactorial origin; absorption, elimination,
Cytochrome P450 system (isoenzyme CYP3A4), gender, liver or urinary clearance,
drug-drug interaction or co-medication for other diseases 8;39;40-43. This study
was not intended to look at these factors although we compared the latter two
factors between the groups and did not find significant differences. In addition,
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in the controls as well as the LA patients one third were females. Another 
explanation for the differences in plasma drug levels between the groups might
be adherence. However, we looked also at levels of concomitant used PIs or
NNRTIs and these levels were overall within the normal range and there were 
no differences between the groups. 
Our study was a retrospective analysis. There are only a few prospective studies 
that have examined the utility of plasma drug concentrations in the treatment of
HIV-infection 36;44. More prospective studies have to be performed in order to get
more insight in the use of plasma drug monitoring for antiretroviral therapy and
its decision making in case of toxicity. It also would be helpful to investigate 
the use of lower dose of stavudine more closely, given the increasing number 
of HIV-infected patients in developing countries were stavudine is used widely,
owing to low costs and inclusion in generic fixed-dose combination drugs.
Decrease of stavudine dosing might result in additional cost- and side effect
reduction. 
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Abstract
The aim of the study was to investigate if higher plasma lopinavir concentrations lead
to increase of serum lipids, one of the major adverse events in patients on lopinavir. 
Plasma drug concentrations were analysed up to week 24 in a prospective 
cohort of HIV antiretroviral therapy-naive patients who started on a regimen 
of zidovudine, lamivudine and ritonavir-boosted lopinavir.
Prospectively we measured plasma lopinavir concentrations from baseline to
week 24 in 72 naive HIV-patients starting on lopinavir (59 males and 13 females).
A total of 210 samples were analysed, with at least two samples in every patient.
Mean LPV trough concentration was 4.3 mg/L (± 2.1). The median intra-subject
variation in LPV level was 38% (range 4-111%).
Serum lipids were not correlated to LPV plasma concentrations possibly due to
the wide intra-individual variability in LPV trough levels. Monitoring of plasma
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Introduction
The high incidence of the metabolic syndrome in human immunodeficiency virus
(HIV)-patients on antiretroviral therapy (ART) containing protease inhibitors (PIs) 
is an increasing clinical problem in HIV treatment. Lopinavir (LPV) is a potent PI,
which is recommended in therapy-naive as well as heavily pre-treated 
HIV-patients (co-formulation with a low dose ritonavir; LPV/RTV).
Together with abdominal discomfort and diarrhoea, hyperlipidaemia are among
the most described adverse events in patients receiving lopinavir. Grade 3 or
higher hypercholesterolaemia and hypertriglyceridaemia have been reported 
in around 10% of antiretroviral therapy-naive patients and in up to 30% of
patients with prevous PI-experience 1-4. Patients with initially high lipid levels 
are at higher risk of developing (severe) hyperlipidaemia. The pathogenic 
mechanism of this dyslipidaemia is multifactorial and includes effects of the 
virus itself and antiretroviral use 5.
Measurement of antiretroviral plasma concentrations has been proven to be useful
for guidance in HIV-therapy, not only for adequate virus control but also for
reducing adverse events. A series of trials have demonstrated the relationship
between plasma levels of antiretrovirals and the presence of side effects 6-8. 
For example, Gatti et al discovered a clear relationship between ritonavir plasma
concentrations and side effects 9. Our own investigation demonstrated higher
stavudine levels in patients experiencing lipoatrophy.10 Previous data showed 
that higher plasma lopinavir concentrations are associated with a higher risk
of elevated cholesterol levels 11;12. 
The free study (ClinicalTrials.gov NCT00405925) is a prospective multicenter 
cohort of HIV-patients starting with ART. In this study therapy-naive patients
started on zidovudine, lamivudine and ritonavir boosted lopinavir to achieve 
an undetectable viral load in short term. Patients with an undetectable viral 
load between week 12 and 24, were randomised to either continuation of the 
initial therapy or switch to 3 NRTIs (trizivir® b.i.d.: each tablet contains 300 mg
zidovudine, 150 mg lamivudine and 300 mg abacavir) in order to simplify
treatment, facilitate drug adherence and prevent potential long term PI-toxicity.
Within the FREE study we investigated whether serum lipid elevation was 
correlated to LPV exposure. 
Methods
Study design
The FREE study is a prospective, multi center cohort in which ART-naive HIV-
infected patients were initially treated with zidovudine, lamivudine and ritonavir
boosted lopinavir. When patients received undetectable viral load between week
12 till week 24, they were randomised to either continuation of this drug regimen or
treatment with zidovudine, lamivudine and abacavir as a fixed-dose combination
drug (trizivir®). In this substudy we measured lopinavir plasma levels in all
patients up to randomisation (maximum week 24). 
A total of 146 patients who started antiretroviral therapy between March 2003 
and January 2006 were consecutively observed up to week 24. 
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Measurement of lopinavir plasma drug concentrations 
Lopinavir plasma concentrations were determined by a high-performance liquid
chromatography (HPLC) assay as previously reported. The lower limit of quantification
is 0.07 mg/L. Average accuracy ranged from 97-106% and precision ranged from
2.4-8.1%, with inter-assay coefficient of variation 2.3-5.9% 13. 
Study population
Inclusion criteria in the cohort included: ≥18 years of age, HIV-seropositivity,
necessity to begin treatment with ART and informed consent. Inclusion criteria
were: male or females older than 18 years, able and willing to sign informed 
consent, CD4 count ≤350/mm3 and HIV-1 RNA ≥30.000 copies/ml. The following
metabolic parameters were required for inclusion: Fasting glucose ≤7 mmol/L
(non-fasting <11 mmol/L), fasting triglycerides ≤2 mmol/L and LDL-cholesterol 
≤4 mmol/L or LDL/HDL ration ≤4.1. Patients with lipids or glucose levels increasing
above the inclusion values (triglycerides >8 mmol/L) could be switched to trizivir®
after week 18 if their viral load had become undetectable (<50 copies/ml).
Otherwise (no undetectable viral load at week 24 or lipid increase before 
randomisation) they were defined as failures and discontinued the original 
study, however their lipid and LPV data could still be used for our subanalysis.
Patients enrolled in this ongoing trial comparing LPV/RTV with abacavir were
selected for this analysis. Every patient started with LPV/RTV in combination with
zidovudine and lamivudine. Follow-up visits were carried out by each individual
center at fixed timepoints, according to the study scheme. Nine hospitals enrolled
patients for this trial. Triglycerides and cholesterol were measured at baseline,
week 4, week 8, week 12, week 18 and week 24. Plasma lopinavir levels were
measured in all patients up to randomisation (week 4, 8, 12, 18 and 24 dependent
on whether the patient was randomised to the LPV/RTV ongoing arm). In order to
get a representative impression of the overall LPV exposure patients with at least
2 LPV trough levels were included in this study. 
Patients were not allowed to use hypolipidemic medication. Lopinavir/ritonavir
was given in a fixed dose combination of 133/33 mg three capsules twice daily
(the former formula kaletra® capsules). For the evaluation of HIV-infection CD4
cell count and viral load were measured at baseline and at week 12 and 24. 
Statistics
Statistical evaluation was performed with SPSS for windows, version 14.0. Mean
and median values with 95% confidence intervals were calculated for all 
samples in each individual. For the analysis, a p-value of ≤0.05 was regarded 
as significant. 
Ethics
The research protocol was approved by the National Medical Ethic Committee 
and written informed consent was obtained from all subjects. 




From the beginning of the study in March 2003 to January 2006 146 patients were 
included, in 132 patients LPV plasma samples were collected, in 93 patients
lopinavir trough levels could be calculated and were enrolled for this analysis.
Because LPV levels within 4 hours after dosing do not allow a representative 
calculation of trough concentrations, we did not use these levels for the analysis.
All data of patients were collected from baseline till randomisation. Four patients
were not enrolled due to incomplete lipid data. Since an elevated plasma 
concentration can be obtained during one of the visits, whereas the overall drug
levels would be adequate, we enrolled only patients with at least two plasma LPV
trough levels to get a representative overall impression of the mean individual
drug levels. There were 17 patients left out of the study due to <2 LPV samples.
Prospectively we measured plasma lopinavir concentrations in 72 naive HIV-
patients starting therapy with zidovudine, lamivudine and ritonavir boosted
lopinavir (59 males and 13 females) until randomisation (between week 12-24).
Five patients used LPV until week 12, three patients until week 18 and of 64
patients we had LPV plasma data until week 24. 
A total of 210 samples were analysed; 32 patients had 2, 22 patients had 3, 10 had
4 and 8 patients had 5 LPV trough levels. The range of samples per patients varied
from 2 to 5 with a mean of 2.9 samples per individual. The mean age at the start of





Mean age (years) 44 ± 9 
Mean CD4 cells (cells/mm3) 170 ± 94






2 samples 32 patients
3 samples 22 patients
4 samples 10 patients
5 samples 8 patients
BMI (kg/m2) 22.9 ± 3.5 
Data until week 12 5 patients
Data until week 18 3 patients
Data until week 24 64 patients
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the study was 44 ± 9 years. The majority of patients were Caucasian (n=49, 68 %),
there were 19 Black patients (26%) and 4 Asian (6%). The mean CD4 cell count at
initiation of the study was 170 ± 94 cells/mm3. Characteristics of the groups are
depicted in table 1. 
During the study period 64 (89%) patients experienced an increase in cholesterol.
An increase of triglycerides compared to baseline was seen in 61 (85%) patients.
None of these patients were treated with lipid lowering drugs. Grade 2 hyper-
cholesterolaemia (>6.2 mmol/L; WHO toxicity scale) and hypertriglyceridaemia 
(>4.5 mmol/L) was seen in 10 (14%) and 6 (8%) patients respectively, of whom 
4 (6%) had even grade 3 hypercholesterolaemia (>7.8 mmol/L) and only 1 (1.4%)
had grade 3 hypertriglyceridaemia (>8.5 mmol/L). LDL-cholesterol >4.8 mmol/L
is an indication for lipid lowering drugs. Only one patient had a serum LDL- 
cholesterol above this threshold, which was 6.4 mmol/L 24 weeks after start of
LPV. This patient had a median LPV trough level of 4.6 mg/L compared to a 
median trough level of 4.0 mg/L for all patients. 
Mean LPV trough concentration was 4.3 mg/L (± 2.1) and median 4.0 mg/L. 
Mean and median trough levels of LPV >8 mg/L were seen in 6 and 5 patients
respectively. Mean and median trough levels of LPV >8 mg/L were seen in 6 and 




















figure 1   Cholesterol changes and lopinavir trough concentrations.
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We did not found a correlation between lipids (cholesterol and triglycerides) 
and LPV trough concentrations (figure 1 and 2). We found a remarkable wide 
inter-subject variation concerning the LPV trough levels with a median of 38%
(range 4-111%).
As far as risk factors are concerned, slightly higher lopinavir through levels were
observed in females compared to males however without statistical significant
difference (4.8 and 3.4 mg/L in females and males respectively). In addition, no
relation between LPV levels and race, age, BMI, CD4 cell count, HIV-RNA and CDC
classification could be detected. 
Discussion
Our data confirm results of previous studies that revealed dyslipidaemia in
patients on LPV. However, we could not demonstrate a correlation between
lopinavir trough levels and dyslipidaemia. In addition, no other factors 
influencing lipid levels were defined. 
There is a wide inter- and intra-patient variability when measuring drug exposure























figure 2   Triglycerides changes and lopinavir trough concentrations.
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ranged from 4-111% with a median of 38%. This phenomenon might explain why
no relation between LPV levels and serum lipids were detected. High variability
in LPV concentrations has been found in several studies ranging from 15-54%; 
median of 35% 14;15. This phenomenon might be an explanation why no 
correlation between LPV trough levels and serum lipids could be detected. An
alternative explanation might be that lipid alterations in LPV use is an intrinsic
adverse event of LPV, independent of LPV concentrations.
There have been a number of studies looking at different aspects of PI drug levels
and the influence on serum lipids. Results from these studies show conflicting
data about relations between drug concentrations and lipids. González De
Requena et al investigated lipids in HIV-patients on salvage therapy with LPV/RTV
from baseline to month 3. They found a positive correlation between the 
percentage increase in triglycerides and LPV trough levels, but no correlation was
found between LPV trough levels and the percentage of increase in cholesterol
levels 12. In a small population all patients with higher LPV trough (especially
trough levels >8 mg/mL) levels were the ones at risk of dyslipidaemia 16;17.
Moreover, in a population of 142 ART-experienced patients high triglycerides 
were found in subjects with high LPV residual concentrations 11. In contrast to the
PharmaAdapt study, where no relationship was demonstrated between PI drug
concentrations and lipids between week 0 and 32 in 252 patients 18. At week 24
increase of triglycerides and total cholesterol could not be correlated with LPV
plasma levels by Leon et al in a population of 26 patients 19. Additionally, in 
a study by Torti et al no correlation between lipid abnormalities and LPV
plasma concentrations were seen 20. These were all trials in heavily pre-treated
HIV-patients.
Of the PI-group lopinavir has been the most frequently associated with hyper-
lipidaemia. A retrospective study comparing patients on an indinavir/ritonavir
(IDV/RTV) with a LPV/RTV containing regimen, noted higher serum cholesterol 
levels in the IDV/RTV group at 3 and 12 months 21. Whereas, Antoniou et al could
not detect a significant difference in lipid alterations between ritonavir boosted 
indinavir and ritonavir in a small cohort of HIV-patients 22. However, these trials
did not investigate plasma drug levels.
Elevated lipid values at baseline and high dietary fat intake are risk factors for
hypertriglyceridaemia and hypercholesterolaemia 23. These confounding factors
could not have played a role in our study because of strict criteria for inclusion
and the measurement of fasting serum lipids. Other advantages of this study are
the prospective design, the homogenous study population, the sample size and
no confounding by the use of statines or fibrates (lipid lowering drugs were only
allowed after randomistation). 
However, some limitations of our study should be noted. First, no RTV levels were
measured therefore the influence of this low dose booster PI cannot be ruled out.
Second, not from all patients there were 5 LPV samples taken up to randomisation.
This study only analysed data till week 24. We might have missed the occurrence
of hyperlipidaemia as a result of longer duration of treatment, independent of
lopinavir plasma concentrations. However, the increase of serum lipids was
already within 24 weeks of LPV use in our ART-naive patients. Others also found
lipid elevations even after short term use of LPV 19;24.
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Data of lipid changes and LPV plasma levels after week 24 are needed for a better
knowledge of the effect of LPV levels on lipids. The total analysis of the FREE study
might give more insight in this issue. Of note, a retrospective analysis of HIV-
infected patients on LPV/RTV revealed increase of total cholesterol and triglycerides
early after introduction of LPV which remained subsequently stable for a period 
of 15 months 3. Finally, the overal incidence of grade 3 or more hyperlipidaemia
might be underestimated due to the strict criteria for inclusion and continuation
of the study. The percentage of patients presenting grade 2 or more hyper-
lipidaemia was lower during the study period compared to other studies.
However, the populations described in literature were heterogenous and even
started with increased serum lipids due to previous therapy or stage of HIV-disease. 
Favourable changes in lipids and lipoproteins have been found in HIV-infected
patients treated with a regimen of stavudine, didanosine and nevirapine 25. 
An overall increase of HDL-cholesterol was seen in these patients compared to
those treated with stavudine and didanosine combined with either lamivudine 
or indinavir. It is remarkable that some studies showed that NRTIs might have 
an additional effect on the development of lipid increase while others did not 26.
It is important to keep in mind that maybe LPV trough levels are not the best
tool to investigate adverse events such as hyperlipidaemia. In order to gain 
further insight into the relevance of LPV plasma concentrations and lipid increase, 
additional studies have to be performed using peak levels. It might be possible
that peak concentrations are the best representative to detect a correlation.
As a consequence of lower volume of distribution female patients are tend to 
be more prone for side effects, which has been observed in some clinical trials 27.
Slightly higher lopinavir levels were observed in females compared to males 
however statistical significant difference could not be reached. 
Our study was not intended to look at risk factors or to define predictive factors 
of hyperlipidaemia, just to investigate the influence of LPV plasma levels.
Ritonavir boosted lopinavir is frequently associated with a significant increase in
triglyceride and/or cholesterol levels soon after starting therapy. It is hypothesised
that this dyslipidaemia is multifactorial and includes a direct effect of the PI 
and a more complex mechanism involving immunologic, genetic and 
pharmacodynamic factors and HIV-infection itself 5;12;16;17;24.
To our knowledge this is the first prospective study analysing LPV levels with
serum lipids in a cohort of only antiretroviral therapy-naive patients. Based on
our data we cannot recommend frequent measurements of serum (trough) levels
in lopinavir use in order to prevent dyslipidaemia. 
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General discussion
With the currently available antiretroviral drugs eradication of HIV-infection is 
still impossible. Even as a chronic disease, HIV continues to be a potentially
life-threatening infection, as disease progression can occur rapidly if treatment is
suboptimal or toxicity leads to discontinuation of medication. In addition, two
other risks in chronic HIV-infection play an important role in morbidity nowadays.
First, as the prognosis for HIV-infected patients steadily improves, these individuals
will incur an increased risk for atherosclerosis resulting in cardiovascular disease.
The cardiovascular risk profile caused by the HIV-infection and by antiretroviral
therapy (ART) will even enhance this problem. A recent study collecting data of
adverse events in ART, stated that ART was associated with a 26% relative increase
in the rate of myocardial infarction per year of exposure during the first 4-6 years
of use. An interesting report that was recently published by Sabin et al (DAD
study), demonstrated an increased risk of myocardial infarction in patients
exposed to abacavir and didanosine within the preceding 6 months and was not
present beyond 6 months after drug cessation. Second, although ART can (partly)
reconstitute the human immune system, it is still not optimal and patients are
high risk for all kind of malignancies. Especially lymphomas and lung carcinoma
are frequently diagnosed. 
The management of HIV-infection is nowadays characterised by easier treatment
schedules than in the beginning of highly active antiretroviral therapy (HAART). 
For example, a previously used drug scheme with saquinavir consisted of at
least 6 tablets three times a day taken with high fat meals combined with 3
tablets of NRTIs twice a day. In sharp contrast, in 2008 a capsule with 
tenofovir-emtricitabine-efavirenz is on the market which reduces the 
burden of tablets to one o.i.d.. 
However drug interactions and a wide scale of adverse events are still present
and often hamper continuation of chronic therapy. In salvage therapy, sometimes
complex treatment schedules with fat intake are needed in order to attain 
effective plasma drug levels to suppress viral replication, with the additional 
risk of side effects. 
Adherence to antiretroviral therapy remains the cornerstone of treatment success.
The major reason for discontinuation of therapy in HIV-infected patients appeared
to be toxicity. Analysis of data from the Dutch HIV monitoring database showed
that in therapy-naive HIV-patients, adverse events were the major reason for
switching ART (44-58%). Additionally, 56% of switches on subsequent regimens
have been attributed to toxicity. 
In management of patients on antiretroviral therapy, identification of possible
factors that make patients prone for toxicity is essential. The benefits of HIV
treatment have to outweigh the disadvantages of antiretroviral therapy. In 
this light the aim of this thesis is to analyse correlations between laboratory
investigations, plasma drug concentrations and toxicity and to identify factors 
to prevent adverse events.
Several issues of toxicity are highlighted in this thesis. First of all, NRTI-related
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toxicity, which has been recognised as mitochondrial dysfunction. Adverse events
related to mitochondrial toxicity are (cardio)myopathy, neuropathy, pancreatitis,
hepatic steatosis and lactic acidosis. Second, the metabolic syndrome with lipid
alterations and insulin resistance is an important adverse event in PI-use, often
seen in combination with body shape changes with fat loss (lipoatrophy) or fat
accumulation (lipohypertrophy); the so-called lipodystrophy syndrome. 
In chapter 1 an overview is given on the emergence of adverse events in anti-
retroviral therapy of HIV-infected patients. Especially NRTI-related mitochondrial
toxicity and lipoatrophy/lipodystrophy with lipid changes and impaired glucose
tolerance are reviewed. Mitochondrial toxicity has been hypothesised as the
mechanism underlying for the pathogenesis of various adverse events associated
with the use of nucleoside reverse transcriptase inhibitors. NRTIs are supposed to
interfere with an enzyme (polymerase γ), essential for the synthesis of mito-
chondrial DNA strands. The triphosphate compounds of the nucleoside analogues
inhibit polymerase γ. Blocking of this enzyme results in mitochondrial damage
and thereby mitochondrial dysfunction. By interference with this enzyme, NRTIs 
are build into a new mitochondrial DNA strand instead of the normal nucleosides,
resulting in chain termination and thereby impaired DNA synthesis. Incidences of
mitochondria-related toxic symptoms are not well known and vary, dependent on
the analysis; neuropathy occurs in 12-46% (with stavudine and didanosine use),
myopathy in 17% (with zidovudine use) and pancreatitis in 0.5-7% (didanosine
and lamivudine). The incidence of lactic acidosis is estimated around 1.3 per 1000
person-years, based on retrospective analysis of a cohort of antiretroviral drug
users. 
Exposure to protease inhibitors has been associated with the development of
significant metabolic adverse effects such as hyperlipidaemia, hyperglycaemia 
and insulin resistance, peripheral fat wasting and central adiposity (neck and 
visceral fat). 
The prevalence of lipodystrophy varies widely. Previous data from the Dutch
ATHENA cohort showed an incidence rate of 6.2 per 100 person years with a 
four-year cumulative incidence of 25%. Pathogenesis of the metabolic syndrome
in HIV-patients is multifactorial and includes effects of inflammation and the
virus itself, effects of antiretroviral drugs on metabolic pathways and drug-
associated adipose repartitioning with subsequent development of insulin 
resistance and lipid alterations. 
In chapter 2 we describe four patients in whom fatal lactic acidosis occurred due
to the use of NRTIs. The initial symptoms were nausea and vomiting, at this stage
the lactic acidosis was not recognised. However when tachypnoea occurred to
compensate the acidosis, the physicians discovered the reason of the symptoms,
i.e. the lactic acidosis. However, despite extensive treatment in the intensive care
departments the complications were fatal when liver failure and uncontrollable
arrhythmias occurred. These four cases illustrate the importance of early recognition
of lactic acidosis. Although co-enzyme Q, thiamine, L-carnitine and riboflavin
have been used, there is no established treatment. The use of riboflavin in one 
of our cases was unsuccessful. Our report of these four cases of fatal lactic acidosis
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revealed that all patients already experienced some kind of NRTI-related toxicity
before this fatal event.
In order to investigate mitochondrial toxicity as the basis for NRTI-induced
adverse events, we analysed serum lactate and pyruvate levels which is described
in chapter 3. There were four groups: patients with presumed NRTI-related
adverse events, patients without adverse events, HIV-infected patients without
antiretroviral therapy and healthy controls. The mean duration of NRTI treatment
was 18 months. The highest lactate levels were found in the patients experiencing
NRTI-related adverse events, especially in patients with stavudine-induced 
neuropathy. The lowest levels were measured in the healthy controls. Remarkable
was that all patients with a lactate value above 2700 µmol/L experienced adverse
events and that the majority even suffered from more than one NRTI-related
adverse event. Just like the fatal cases, these patients were all on a stavudine
containing regimen. Looking at the adverse event neuropathy more closely, we
found that the highest lactates were measured in patients with NRTI-related 
neuropathy. This is consistent with a study using serum lactate levels in 
distinguishing between HIV- and NRTI-associated neuropathy. Neuropathy is 
an important cause of switching HIV-treatment and one of the reasons for the
unpopularity of stavudine and didanosine. Asymptomatic mild hyperlactataemia
is a rather common feature of antiretroviral therapy. Mild asymptomatic 
hyperlactataemia requires careful monitoring but no immediate action. In 
case symptoms occur that might be due to side effects of NRTIs, hyperlactataemia
might be of additional value to distinguish the cause of these symptoms. We
advise to measure serum lactate concentrations in these patients. In addition,
from our data we suggest that lactate levels of ≥2500 µmol/L (even in asympto-
matic patients) need careful attention and eventually discontinuation if lactate
concentrations stay high or if symptoms occur. Patients with stavudine-related
neuropathy and long term antiretroviral therapy (mostly second or more regimens)
are prone for symptomatic hyperlactataemia. Hyperlactataemia in patients on
stavudine is noticeable and not always directly related to adverse events. We
would not recommend routine measurement of lactate during antiretroviral 
therapy in all asymptomatic patients. However, serum lactate measurement is
useful in patients with NRTI-related adverse events. In patients with serum 
lactates above 2500 µmol/L, we would advise frequent monitoring in order to
evaluate if discontinuation of the current antiretroviral therapy is needed. 
The other study measuring lactates in different groups of HIV-patients is described
in chapter 4. This is an additional study to the previous trial. Since an oral 
glucose tolerance test (OGTT) can diagnose mitochondrial dysfunction in patients
with inherited mitochondrial disorders, our aim was to test whether an OGTT is
useful for the detection of (occult) hyperlactataemia as a result of NRTI-related
toxicity. We performed an OGTT in HIV-patients with and without NRTI-related
mitochondrial toxicity. By this approach we showed that an OGTT is useful as an
additional test to find hyperlactataemia in mitochondrial related toxicity. On the
basis of the sensitivity and specificity we illustrated that an OGTT in patients 
suspected of mitochondrial related toxicity is useful to distinguish toxicity from
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other symptoms. However, an OGTT should not be used as a routine screening in
asymptomatic patients on antiretroviral treatment. The use of an oral glucose 
tolerance test is worthwhile in symptomatic patients on antiretroviral therapy to
confirm NRTI suspected mitochondrial toxicity. Hyperlactataemia after glucose
loading reflected the patients with NRTI-related adverse events. Because of its 
low sensitivity but good specificity, an OGTT should be used as an additional 
test to verify NRTI-related toxicity rather than to search for NRTI-related toxicity. 
In both previously described studies we found that duration of therapy is an
additional risk factor for the development of mitochondrial toxicity in NRTI-
treatment. 
One of the most expanding problems, which have been underestimated in the
first years of highly active antiretroviral therapy, is the lipodystrophy syndrome,
with lipohypertrophy and lipoatrophy. Exposure to PIs has been associated with
the development of metabolic adverse effects such as hyperlipidaemia, insulin
resistance and central adiposity. Peripheral fat wasting (lipoatrophy) is associated
with NRTI and especially stavudine use. Given the multifactorial pathogenesis of
this syndrome, we wanted to analyse metabolic changes in more detail, especially
since the high incidence of the metabolic syndrome in ART-use means an increase
in cardiovascular co-morbidity. In chapter 5 we present the results of metabolic
parameters in a prospective study treating antiretroviral naive patients. Since
antiretrovirals are known to cause lipid alterations and glucose intolerance, it is
becoming increasingly important to make an adequate risk profile for cardiovascular
diseases in patients treated with antiretrovirals. Our results provide more insight
into the existence of these metabolic changes. The data show a lipid increase and
impaired insulin sensitivity in the first 24 weeks of ART (lopinavir use). After week
24 this elevation becomes stable in lopinavir users. In contrast to the subjects that
continued on abacavir. There was a significant difference between the PI group
and the triple NRTI group. The PI-free group (triple NRTI use) demonstrated a
decrease of serum lipids and improved glucose tolerance after initiation, 
while in the PI containing regimen lipid and glucose increase stabilised. 
Like other investigators we demonstrated that PI regimens are associated with
changes in lipoprotein profiles and thereby an increased risk of cardiovascular
disease. However this is the first prospective trial investigating extensive metabolic
parameters in naive patients starting on PI with randomisation to a PI free regimen
(abacavir) or continuation of PI at week 24. 
The lipohypertrophy/lipoatrophy syndrome has not only major psychosocial 
implications for patients suffering from this condition it also has impact on the
life-expectancy by introducing cardiovascular risk factors both influencing 
treatment adherence. Miscellaneous reports highlight the fact that lipodystrophy,
mainly the lipoatrophy component, is primarily linked to NRTI therapy, in 
particular stavudine, while dyslipidaemia and insulin resistance are associated
with PI therapy. For these reasons we investigated the role of drug concentrations
in the occurrence of lipoatrophy and dyslipidaemia. We performed two studies:
one regarding the correlation between stavudine plasma concentrations and
lipoatrophy, the other investigating plasma lopinavir concentrations in relation 
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to serum lipids. In chapter 6 the relation between lipoatrophy and plasma 
stavudine concentrations is investigated. We retrospectively measured stavudine
plasma concentrations in patients with and without lipoatrophy. Plasma 
stavudine concentrations were higher in the group with lipoatrophy compared 
to patients without lipoatrophy. Although it is stated that plasma NRTI 
concentrations do not correlate with the active triphosphate NRTI metabolite
which is intracellular, our data show that measurement of NRTI plasma 
concentrations can be useful as a derivative of NRTI-induced toxicity. On the 
basis of recent published data and those of our study, we suggest that a plasma
stavudine concentration ratio <1.0 is a safe level for treatment of HIV-patients to
prevent lipoatrophy. Our findings are in line with a recent addendum to the 
WHO-guidelines on antiretroviral therapy for HIV-infection in adults and adoles-
cents, which now recommends a lower dosage for stavudine (30 mg twice daily).
Hypercholesterolaemia and hypertriglyceridaemia are frequently seen in lopinavir
use, incidence rates vary depending on the severity of the increase; grade 3-4
lipid rise has been reported in about 25% of patients. Especially the rise of
LDL-cholesterol makes these patients more prone for cardiovascular diseases. 
A recent cohort showed a prevalence of high LDL in men of around 20% and in
women of around 10%. The percentages were higher than in non HIV-infected
subjects, with a further increased prevalence in patients on PIs. 
To look more closely at lipid alterations as a result of toxicity, we analysed the
plasma lopinavir (LPV) concentrations and lipid levels of the FREE study in 
chapter 7. This study provided a unique opportunity to address this issue as the
initial treatment in all patients was zidovudine, lamivudine and ritonavir-boosted
lopinavir. By using this database of patients in whom fasting serum lipids and
lopinavir concentrations were collected, we could analyse 210 plasma samples in
72 patients. During the study period the majority of the patients experienced an
increase in cholesterol and triglycerides, although a grade 2 hyperlipidaemia 
was only seen in a small population (<10%). This study supports that PI use 
contributes to the development of lipoprotein abnormalities. Lipid increase was
already seen even after short-term PI use. However, serum lipids did not correlate
to LPV plasma concentrations probably due to a remarkable wide intra-individual
variability in LPV trough levels varying from 4-111% (median of 35%) and the
intrinsic effect of LPV on lipid metabolism. We conclude that plasma LPV
measurement and eventually dose adjustment of LPV will not be useful to 
prevent hyperlipidaemia. 
The studies reported in chapter 6 and 7 did not have the intention to determine
causal factors of lipoatrophy and dyslipidaemia, we were just searching for a
potential influence of high drug exposure as risk factor for the occurrence of
metabolic complications and how therapeutic drug monitoring might influence
this in the future. 
The studies described in this thesis represent an overview of different types of
toxicity in antiretroviral therapy in HIV-infected patients. These data show the
clinical relevance of close monitoring of patients on antiretroviral therapy to 
prevent drug toxicity and achieve better adherence. 
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At present no combination of antiretroviral compounds meets all of the 
characteristics of an ideal antiretroviral regimen without any adverse events. 
All different kinds of agents have their advantages and disadvantages. In clinical
practice, the choice of the best antiretroviral regimen should be made after 
careful evaluation of all aspects of HIV-treatment. The best antiretroviral therapy
for this specific patient must be based on a careful balance between efficacy and
safety. The tolerance profile of the individual drugs and the combination of them
in particular should be taken into account when choosing antiretroviral 
medicines. With the help of therapeutic drug monitoring of NRTIs, NNRTIs and PIs
toxicity can be prevented or detected in an early and still reversible phase. This
individual approach makes HIV-treatment a challenging business for every
physician treating this kind of chronic infections. 
In the next years, we expect new agents in the already existing classes of NRTIs,
NNRTIs and PIs, but also new drugs from the more recent introduced classes of
antiretrovirals such as integrase and fusion inhibitors as well as chemokine 
receptor blockers. The type of toxicity occurring in antiretroviral therapy seems 
to be class specific, this might implicate that with the introduction of new
antiretrovirals also new kinds of adverse events will be seen. As the future 
might bring us numerous other adverse events with the release of new drug
classes, which deserve scientific attention for their severity or their effect on
quality of life, we would welcome more studies in this field. An interesting new
field in pharmacotherapy is pharmaco-genetics. Genetic constitution plays a role
in adverse events. By exploring this field, more individualised therapy can be
applied resulting is less side effects. 
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Samenvatting 
Met de huidige beschikbare medicijnen voor HIV-infectie (HIV: humaan 
immunodeficiëntie virus) is het mogelijk om deze potentieel dodelijke ziekte 
tot staan te brengen. Genezing is echter helaas niet mogelijk gebleken. De 
vermenigvuldiging van het virus is goed te onderdrukken, maar uitroeiing ervan
lukt nog steeds niet. Door continu gebruik van HIV-onderdrukkende medicijnen is
HIV-infectie een chronische ziekte geworden. Maar zelfs als chronische ziekte blijft
HIV nog steeds een potentieel ernstige infectie met soms dodelijke afloop. Zo kan
ziekteprogressie snel optreden als de behandeling niet optimaal is of als 
bijwerkingen leiden tot het staken van de medicijnen. Er spelen twee belangrijke
klinische problemen in chronische HIV-infectie. 
Allereerst, de ouder wordende HIV-patiënt zal net als individuen zonder HIV
aderverkalking krijgen met het toenemen van de leeftijd, terwijl deze kans nog
meer toeneemt door HIV-infectie zelf en door de antiretrovirale therapie. Een 
van de belangrijkste problemen op dit moment bij het chronisch gebruik van
antiretrovirale medicijnen bij HIV zijn stijging van cholesterol en vetten in het
bloed (triglyceriden) en neiging tot suikerziekte (ongevoeligheid voor insuline). 
Dit wordt met name gezien bij het gebruik van de zogenaamde protease remmers
(Engels: protease inhibitors: PIs). Deze afwijkingen kunnen leiden tot hart- en
vaatziekten. Recent toonde een onderzoek dat behandeling met HIV-medicijnen
(antiretrovirale therapie) gepaard gaat met een relatieve toename van 26% in het
aantal hartinfarcten per jaar in de eerste 4-6 jaar van antiretrovirale therapie.
Een andere studie toonde een toename in het aantal hartinfarcten bij patiënten
die abacavir en didanosine gebruikten. Dit toegenomen risico verdween 6 
maanden na het staken van deze medicijnen. Met name omdat de leeftijd van
patiënten met HIV-infectie steeds hoger wordt, mag verwacht worden dat dit
probleem in de toekomst groter zal worden. Immers de kans op aderverkalking 
en daarmee de kans op hartinfarcten of een beroerte, wordt groter naarmate 
men ouder wordt. 
Het tweede belangrijke probleem bij chronische HIV-infectie is het maar 
gedeeltelijk herstel van de afweer. Dat is waarschijnlijk de belangrijkste reden 
dat er bij HIV-patiënten meer kanker voorkomt dan bij de normale bevolking. 
De huidige HIV-therapie bestaat in de regel uit een combinatie van drie genees-
middelen uit tenminste twee klassen. De inname is een stuk eenvoudiger 
geworden in de afgelopen tijd. Een voorheen gebruikt medicatieschema met
bijvoorbeeld de proteaseremmer saquinavir bestond uit 3 maal daags 6 tabletten
die ingenomen moesten worden met een vetrijke maaltijd, gecombineerd met
2 maal daags 3 tabletten uit een andere klasse medicijnen; de nucleoside reverse
transcriptase remmers (Engels: nucleoside reverse transcriptase inhibitors: NRTIs).
Dit is een groot contrast met tegenwoordig. Onlangs is een combinatiemedicijn op
de markt gekomen dat uit drie componenten bestaat: tenofovir, emtricitabine en
efavirenz. Hiermee is het mogelijk geworden om HIV-infectie te behandelen met
één keer per dag één tablet. Naast deze voordelen zijn er nog steeds veel 
nadelen. Interacties tussen medicijnen en bijwerkingen zijn een belangrijk
probleem bij het chronisch gebruik van HIV-medicatie. 
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Niettemin wordt deze één maal daags behandeling niet door alle patiënten 
verdragen. Slaapstoornissen, duizeligheid, hallucinaties, afwijkingen in botten en
nieren kunnen voorkomen. Ook zijn er nog onvoldoende lange-termijngegevens
om te kunnen stellen dat het hier een perfect werkzame en veilige behandeling
betreft. Daarom blijft er ook voor de andere antiretrovirale geneesmiddelen een
plaats in de behandeling. 
Dit proefschrift gaat over de bijwerkingen van antiretrovirale medicijnen bij HIV
(met name de PIs en de NRTIs). Therapietrouw is de belangrijkste hoeksteen van
succesvolle therapie. Dit was in elk geval tot voor kort een belangrijk probleem.
De belangrijkste reden voor het staken van medicatie is het optreden van 
bijwerkingen. Een analyse van gegevens uit de Nederlandse HIV monitoring 
databank toonde dat 44-58% van de patiënten op hun eerste antiretrovirale
therapie hun medicatie stopten vanwege bijwerkingen. Dit was 58% bij daarop
volgende therapieën. Dit benadrukt hoe belangrijk veiligheid is. Bovendien is 
het van belang factoren op te sporen die een rol spelen bij het optreden van
bijwerkingen. De voordelen van therapie moeten opwegen tegen de nadelen 
van bijwerkingen. Met dit doel heeft dit onderzoek zich gericht op de analyse van
verbanden tussen laboratoriumonderzoek, plasmaspiegels van medicijnen en
schadelijkheid (toxiciteit). Daarmee hebben we ook gekeken naar mogelijke 
factoren die een rol spelen bij het ontstaan van bijwerkingen die mogelijk
kunnen worden toegepast voor preventie.
Verscheidene kanten van toxiciteit worden belicht in dit proefschrift. Ten eerste,
de bijwerkingen van de klasse nucleoside reverse transcriptase remmers 
(NRTI-gerelateerde schade). NRTIs veroorzaken afwijkingen in de mitochondriën;
de onderdelen van cellen die zorgen voor de energiehuishouding. Bijwerkingen 
gerelateerd aan mitochondriële schade zijn schade aan de hartspier,
zenuwbeschadiging, alvleesklierontsteking, leververvetting en melkzuurvergiftiging. 
Ten tweede, hebben we studies verricht met betrekking tot het zogenaamde
metabool syndroom. Dit syndroom bestaat uit een ongunstige verandering in de
bloedvetten (lipiden) en de glucose (suiker) stofwisseling, waardoor er suikerziekte
kan ontstaan bij de HIV-geïnfecteerde patiënt. Het metabole syndroom met
lipidenveranderingen en insulineresistentie (neiging tot suikerziekte) is een
belangrijke bijwerking van PI-gebruik. Daarnaast worden er tevens vaak
lichaamsveranderingen gezien bij de patiënt, met verlies van vetweefsel in het
gelaat, de armen en benen, en toename van vet in de buik en de nek (het
zogenaamde lipodystrofie syndroom). Het perifere vetverlies wordt lipoatrofie
genoemd en de centrale vetophoping wordt ook wel lipohypertrofie genoemd. 
In hoofdstuk 1 geven we een overzicht van de mogelijke bijwerkingen ten gevolge
van HIV-behandeling. Met name de zogenaamde schade aan de mitochondriën
ten gevolge van het gebruik van nucleoside reverse transcriptase remmers en 
het lipodystrofie syndroom met de lipidenveranderingen, de afwijkingen in de
glucosestofwisseling en het lipodystrofiesyndroom komen aan de orde. Dit laatste
syndroom werkt erg stigmatiserend, mensen worden herkend door hun uiterlijk.
Het confronteert de patiënt dagelijks met de infectie en de schaduwzijde van de
succesvolle therapie. Deze bijwerking werkt dan ook zeer demotiverend voor de
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patiënt om de (in principe) levenslange therapie vol te houden. Mitochondriële
schade is het mechanisme dat ten grondslag ligt aan het optreden van bepaalde
bijwerkingen bij gebruik van NRTIs. Enkele voorbeelden hiervan zijn hierboven
reeds genoemd; zoals het optreden van leververvetting, bloedarmoede, pijnlijke
zenuwuiteinden van de handen en voeten (polyneuropathie) en spierpijnklachten.
De chemisch structuur van deze NRTIs zorgt ervoor dat niet alleen de vorming van
een nieuwe HIV-RNA-keten (erfelijk materiaal van het virus) wordt geremd, maar
ook de opbouw van een nieuwe mitochondriële DNA-keten van de gastheer kan
worden geblokkeerd. Normaliter worden fouten in het DNA (erfelijk materiaal)
gecontroleerd en eruit geknipt. Dit mechanisme van reparatie werkt zeer goed in
onze celkernen maar is minder effectief in onze mitochondriën. Daarom treedt er
bij het maken van een nieuw mitochondrion eerder schade op dan bij de opbouw
van een nieuwe celkern. Het percentage van deze bijwerkingen is niet goed 
bekend, deze variëren afhankelijk van het soort onderzoek; pijnlijke prikkelingen
in de handen en voeten ten gevolge van zenuwschade (neuropathie) wordt gezien
in 12-46%, spierpijnklachten in ca. 17% en ontsteking van de alvleesklier in 
0.5-7%. Het voorkomen van lactaatacidose (verzuring van het bloed ten gevolge
van overproductie van melkzuur) wordt geschat op te treden in 1.3 per 1000 
persoonsjaren. 
De blootstelling aan protease remmers (PIs) is de belangrijkste oorzaak van de
stofwisselingsproblemen zoals toename van vetgehaltes in het bloed, een hoog
suikergehalte, vetverlies op de armen, benen en deels ook voor de vetophoping 
in de buik en nek (lipodystrofie syndroom). Het verlies van vet in het gelaat en
aan de armen en benen is vooral een bijwerking van NRTIs.
Het optreden van deze bijwerking (verandering van lichaamsvet) is wisselend.
Eerdere data van het zogenaamde Nederlandse ATHENA cohort (huidige naam:
Stichting HIV Monitoring) toonde een incidentie ratio van 6.2 per 100 persoons-
jaren met een cumulatieve incidentie van 25%. Er zijn meerdere factoren die een
rol spelen bij het ontstaan van dit metabool syndroom: ontsteking, het virus zelf
en effecten van HIV-medicijnen op vet- en suikerhuishouding. 
In hoofdstuk 2 beschrijven we vier patiënten die een fatale melkzuurvergiftiging
(lactaatacidose) ontwikkelden ten gevolge van NRTI-gebruik. De eerste symptomen
bij deze patiënten waren misselijkheid en braken. In dit stadium was 
melkzuurvergiftiging als de oorzaak van het probleem nog niet onderkend. Dit
werd gevonden toen hyperventilatie optrad als compensatiemechanisme voor de
verzuring van het bloed. Ondanks intensieve zorg en het toedienen van diverse
medicijnen, ging de leverfunctie achteruit en traden gevaarlijke hartritmestoor-
nissen op. Uiteindelijk zijn alle patiënten overleden. Een van deze patiënten werd
nog behandeld met riboflavin, een middel dat in enkele gevallen gebruikt is voor
de behandeling van lactaatacidose in patiënten met mitochondriële schade. Het
opvallende bij deze patiënten was dat zij allen tevoren al andere bijwerkingen
hadden gehad ten gevolge van NRTI-therapie. Dit illustreert het belang van vroege
herkenning van symptomen veroorzaakt door bijwerkingen. 
Om mitochondriële schade door NRTIs aan te tonen, hebben we in het bloed
melkzuur en pyruvaat (beide stoffen zijn van belang voor onze energiestof-
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wisseling) gemeten in poliklinische patiënten en gezonde vrijwilligers. Glucose
(suiker) wordt in de cel omgezet in pyruvaat, dit wordt in het mitochondrion 
via de citroenzuurcyclus verder omgezet met als eindresultaat energie (het
zogenaamde ATP) en koolzuur (CO2). Als de mitochondriën niet goed functioneren
kan pyruvaat niet via de citroenzuurcyclus worden omgezet en wordt het buiten
het mitochondrion via het enzym LDH (lactaat dehydrogenase) omgezet in lactaat.
Deze reactie is omkeerbaar. Met behulp van het meten van lactaat en pyruvaat
wilden we meer inzicht krijgen in het optreden van mitochondriële dysfunctie. 
De resultaten staan beschreven in hoofdstuk 3. Er waren vier groepen: patiënten
met NRTI-gerelateerde bijwerkingen, patiënten zonder bijwerkingen van 
HIV-medicatie, HIV-patiënten die (nog) geen medicatie gebruikten en gezonde
controles. De gemiddelde duur van NRTIs was 18 maanden. De hoogste lactaat-
waarden werden gevonden bij patiënten met bijwerkingen door NRTIs (vooral de
patiënten met zenuwirritatie) en bij patiënten met stavudine-gebruik. De laagste
lactaatwaarden werden gevonden in de gezonde vrijwilligers. Alle patiënten met
lactaatwaarden boven de 2700 µmol/L hadden last van bijwerkingen en de
meerderheid had zelfs meer dan 1 NRTI-gerelateerde bijwerking. Net als de
patiënten beschreven in hoofdstuk 2, gebruikten deze patiënten allemaal 
stavudine. Hoge lactaatwaarden bij patiënten met pijnlijke zenuwuiteinden 
(neuropathie) werden ook gevonden in een ander onderzoek. Hierbij werd
melkzuur-meting toegepast om onderscheid te maken tussen neuropathie 
door HIV zelf of door HIV-medicijnen. Neuropathie is een belangrijke reden om 
therapie te veranderen. Het is ook een van de belangrijkste redenen waarom
stavudine en didanosine niet veel meer gebruikt worden. Een verhoogd 
melkzuurgehalte in het bloed komt vaak voor. Routinematig meten hiervan wordt
niet aanbevolen. Er moet onderscheid gemaakt worden tussen verhoogd melkzuur
met en zonder klachten. Melkzuur-verhoging wordt nogal eens gezien bij 
stavudine-gebruik daarom zijn deze patiënten vatbaarder voor bijwerkingen 
zeker na langdurig gebruik hiervan. Op basis van onze bevindingen zouden we
frequente controle van melkzuur adviseren bij mensen met waarden boven de
2500 µmol/L vooral om te zien of deze waarden niet toenemen en gaan leiden 
tot problemen. Bij toename van melkzuur of duidelijke klachten moet het
betreffende medicijn gestaakt worden. 
In hoofdstuk 4 bespreken we de resultaten van een aanvullend onderzoek waarin
we meer te weten wilden komen over de mitochondriële schade en om na te
gaan of we deze bijwerking met een test in een vroeg stadium kunnen opsporen.
Een orale glucose tolerantie test (OGTT; een test waarbij mensen een suikeroplossing
drinken) wordt gebruikt voor het vaststellen van aangeboren afwijkingen van de
mitochondriën bij kinderen. Wij vroegen ons af of het gebruik van deze test ook
zinvol zou zijn voor onze patiëntengroep met bijwerkingen. Het bleek dat we met
deze test verhoogde melkzuurconcentraties in een vroege fase konden vinden. 
De test is niet gevoelig genoeg als screeningstest, maar wel toepasbaar om een
vermoeden op bijwerkingen te bevestigen. 
Toen de protease remmers (PIs) op de markt kwamen waren een aantal lange 
termijn bijwerkingen nog niet duidelijk. Inmiddels is het lipodystrofie syndroom
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met metabole veranderingen een van de grootste problemen op dit gebied.
Gezien het feit dat meerdere factoren een rol spelen bij het ontstaan en het risico
op hart- en vaatziekten, wilden we in meer detail hiernaar kijken. In hoofdstuk 5
presenteren we de resultaten van onderzoek waarbij uitgebreid bloedonderzoek
werd gedaan bij HIV-patiënten die net starten met hun eerste HIV-behandeling.
In dit onderzoek werden alle patiënten eerst behandeld met zidovudine, 
lamivudine en de proteaseremmer lopinavir/ritonavir totdat de hoeveelheid virus
in het bloed niet meer meetbaar was. Op dat moment werden de patiënten
verdeeld in twee groepen: doorgaan op dezelfde manier of omzetting van
lopinavir/ritonavir in een ander medicijn; abacavir. Protease-remmers staan 
bekend om hun verhoging van cholesterol en vetten in het bloed en neiging tot
suikerziekte. Dit verhoogt weer het risico op hart- en vaatziekten. Het doel van
deze studie was dan ook om na te gaan of de vet- en suikerstofwisseling in 
gunstige zin beïnvloed zou worden met het vervangen van lopinavir/ritonavir door
abacavir (medicijn uit de NRTI-groep). Onze resultaten geven meer inzicht in het
optreden van deze stofwisselingsveranderingen. We vonden een verhoging van
het cholesterol en vetten in het bloed in de eerste 24 weken van de behandeling
(lopinavir gebruik). Na 24 weken nam dit niet meer toe maar werd een stabiele
waarde bereikt bij patiënten met lopinavir. In tegenstelling tot de patiënten die
verder gingen met abacavir. Na de omzetting naar abacavir werd een daling van
het cholesterol en de vetten in het bloed gezien. Bij de groep die
ritonavir/lopinavir bleven gebruiken, traden er geen veranderingen op en ook
geen verdere stijging. Andere bloedtesten die gedaan kunnen worden voor het
bepalen van het risico op hart- en vaatziekten zijn: apoE, apoB, high sensitive
CRP en leptine. Deze waarden toonden geen verschil in beide groepen. 
Onze gegevens bevestigen de resultaten van andere onderzoekers. Ons onderzoek
is echter het eerste onderzoek dat dit heeft bekeken in een groep die net start
met medicijnen. 
De lichaamveranderingen door het lipodystrofie syndroom hebben niet alleen
grote psychosociale gevolgen maar zijn ook van groot belang voor de levens-
verwachting van patiënten door het toegenomen risico op hart- en vaatziekten.
Beide factoren hebben een zeer ongunstige invloed op het dagelijks innemen van
de medicijnen (therapietrouw). Diverse artikelen laten zien dat het vetverlies in
gelaat en armen/benen wordt veroorzaakt door NRTIs en vooral door langdurig
gebruik van stavudine. Ontregeling van de vetten in het bloed en de neiging tot
suikerziekte wordt vooral veroorzaakt door protease remmers. Wij wilden weten 
of patiënten met lipoatrofie wellicht te hoge concentraties van stavudine in het
bloed hadden. In hoofdstuk 6 wordt hiervan verslag gedaan. We hebben hiervoor
concentraties van stavudine in het bloed gemeten bij 2 groepen patiënten:
patiënten met en zonder vetverlies (lipoatrofie; zie foto’s op pagina 22).
Inderdaad bleken de stavudine concentraties hoger te zijn in de groep van 
patiënten met lipoatrofie vergeleken met die zonder lipoatrofie. Op basis van recent
gepubliceerde gegevens en onze studie stellen we dat een concentratie ratio <1.0
veilig kan zijn voor de behandeling van HIV-patiënten om zo lipoatrofie te
voorkomen. Onze bevindingen komen overeen met een onlangs aangepaste
richtlijn van de WHO (World Health Organisation) voor het behandelen van 
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volwassenen met HIV. Deze richtlijn adviseert een lagere dosis van stavudine dan
voorheen gebruikelijk was; 2 x per dag 30 mg in plaats van 40 mg. 
Verhoogd cholesterol en vetten in het bloed worden vaak gezien bij gebruik van
lopinavir. Ernstige stijging van o.a. cholesterol wordt gerapporteerd in 25% van de
patiënten. Vooral de stijging van het ‘slechte’ cholesterol (LDL-cholesterol) geeft
een toename in de kans op hart- en vaatziekten. Een onlangs gepubliceerd
onderzoek toonde een hoog LDL-cholesterol in 20% van de mannen en 10% van
de vrouwen met een HIV-infectie. Deze percentages waren hoger dan in gezonde
personen. Ook werden hogere percentages gevonden in patiënten die protease
remmers gebruikten. Om in meer detail te kijken naar vetveranderingen in het
bloed als bijwerking, hebben we cholesterol concentraties gemeten in het bloed
bij HIV-patiënten. Dit waren mensen die meededen aan de zogenaamde FREE
studie (zie hoofdstuk 5). De resultaten staan beschreven in hoofdstuk 7. In deze
patiëntengroep hebben we onderzocht of er een verband is tussen de veranderingen
in de vetstofwisseling en de concentraties ritonavir/lopinavir in het bloed. Bij 72
patiënten (210 serum monsters) hebben we dit gemeten. Tijdens de studie-periode
kreeg het merendeel van de patiënten een verhoging van het cholesterol in het
bloed. Al na kortdurend gebruik van lopinavir zagen we stijging in het cholesterol
optreden. We vonden echter geen verband tussen de blootstelling aan lopinavir
(concentraties in bloed) en de cholesterolwaarden. Dit is waarschijnlijk het gevolg
van de grote spreiding in lopinavir concentraties binnen de patiënten zelf. 
De lopinavir concentraties varieerden binnen de patiënten (intra-individuele 
spreiding) van 4-111% met een gemiddelde van 35%. De hoeveelheid van het
medicijn in het lichaam lijkt dus geen rol te spelen in deze cholerstoltoename. 
Op basis van onze bevindingen zal verlaging van de dosis geen invloed hebben 
op het voorkomen van cholesterolstijgingen. 
De studies in hoofdstuk 6 en 7 waren niet bedoeld om te kijken naar de 
oorzaak voor vetveranderingen. Ze waren louter opgezet om de invloed van 
medicatie-blootstelling als risicofactor te bestuderen. 
De studies beschreven in dit proefschrift geven een overzicht van de verschillende
soorten bijwerkingen veroorzaakt door HIV-medicijnen. Deze gegevens laten 
zien dat het zinvol is patiënten goed te controleren. Op deze manier kunnen 
bijwerkingen vroeg worden opgespoord of zelfs worden voorkomen. Hierdoor 
is het gemakkelijker voor de patiënten om deze behandeling langdurig vol te
houden. 
Op dit moment kan elke behandeling bijwerkingen veroorzaken. Geen enkele
combinatie van medicijnen is ideaal en zonder bijwerkingen. In de praktijk moet
de keuze van de beste behandeling gemaakt worden na een zorgvuldige afweging
tussen effectiviteit en veiligheid. Hierbij zal ook rekening gehouden moeten 
worden met individuele medische problemen van de betreffende patiënt. Met
behulp van bloedonderzoek kunnen bijwerkingen in een vroege fase opgespoord
worden. Deze individuele aanpak bij de behandeling van HIV-patiënten is een
uitdaging voor elke internist die deze chronische infectie behandelt. 
Inmiddels zijn er nieuwe klassen van geneesmiddelen op de markt gekomen: 
de chemokine receptor remmers en de integraseremmers. De veiligheid van deze
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nieuwe groepen en ook de werkzaamheid op lange termijn staan nog niet vast. 
In de komende jaren zullen nieuwe medicijnen uit de reeds bekende klassen van
PIs, NNRTIs (Engels: non nucleoside reverse transcriptase inhibitors) en NRTIs op de
markt komen. Daarnaast zullen ook de nieuwere klasse medicijnen met andere
aangrijpingspunten op het HIV-virus, uitgebreid worden. De soorten bijwerkingen
die kunnen ontstaan zijn vaak klasse-specifiek. Dit betekent dat bij de komst van
nieuwe medicijnen ook nieuwe bijwerkingen zullen worden gezien. De toekomst
kan ons daarom, nog diverse nieuwe en onbekende bijwerkingen brengen die
wetenschappelijk onderzoek noodzakelijk maken. Daarbij is zowel onderzoek naar
de ernst als het effect op kwaliteit van leven van belang. Het is belangrijk om de
mogelijke bijwerkingen goed te onderzoeken en onderliggende mechanismen te
bestuderen. Een nog nauwelijks ontgonnen terrein is hierbij het onderzoeken van
genetische aanleg voor bepaalde bijwerkingen. Mogelijk dat dit in de toekomst
resulteert in een nog betere individuele HIV-behandeling. 
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Dankwoord
Een proefschrift maak je niet alleen en ook deze was niet tot stand gekomen 
zonder de hulp van velen, zowel voor als achter de schermen.
Bij deze wil ik graag alle patiënten bedanken die altijd belangeloos mee wilden
doen aan onderzoek. Ondanks hun chronische ziekte met alle belasting van dien,
waren zij steeds weer bereid om mee te werken aan extra onderzoeken. 
Professor Dr. Van der Meer, mijn promotor, beste Jos, ik wil je danken voor de
steun bij de tot standkoming van dit proefschrift. Door de combinatie onderzoek
en opleiding konden beiden projecten voortgang vinden. De anekdotes bij de
overdracht waren voor mij steeds een geslaagde start van de dag. 
Dr. Koopmans, co-promotor, beste Peter, dank voor al je geduld, samenwerking
en begeleiding van dit proefschrift. De vele malen dat ik met je mee kon liften
naar besprekingen her en der in het land waren zeer welkom.
Dr. Burger, co-promotor, beste David (mooie naam), dank voor je hulp en heldere
ideeën. Ondanks je volle agenda neem je altijd de tijd voor het beantwoorden
van vragen.
Bert Zomer, Karin Grintjes, Marjolein Bosch, Annemarie Goedhart en Minny
Meeuwissen, jullie zijn niet alleen voor de patiënten maar vooral ook voor de
dokters onmisbaar in de HIV-zorg.
George Borm, beste George, statistiek is niet mijn sterkste kant. Ik ben blij dat
jij dit voor je rekening hebt genomen. ‘Bommen’ gaat me beter af. 
Clemens Richter en Nienke Langebeek, dank voor de prettige samenwerking bij
het onderzoek.
Mirian Janssen, beste Mirian, dankzij jou kon ik onderzoek, opleiding en thuis mooi
combineren. Je bent de ideale duopartner: nooit lag er werk van de vorige dag.
Nico Molenaar, beste Nico, ik ben je dankbaar voor de mooie omslag van dit
proefschrift. Daarnaast denk ik met plezier terug aan het tropische paradijs op A52. 
Willem Teunissen, beste Willem, ik wil je danken voor de mooie vormgeving van
dit proefschrift en vooral ook voor het uit handen nemen van veel ‘last minute’
werk. 
Patricia Hugen, beste Patricia, het is geweldig om onderzoek te doen met iemand
die alles zo goed regelt. Ik heb er veel van geleerd. 
Verder ben ik dank verschuldigd aan: alle co-auteurs, laboranten van het lab AIG,
al mijn kamergenoten van de afgelopen jaren, de ‘infectiemeisjes’ en Eva.
Marja en Marieke jullie zijn al jaren een klankbord voor lief en leed, ik koetser
jullie waardevolle en langdurige vriendschap. 
Judith, dank voor al je computerhulp en bruikbare tekstuele ideeën.
Arthur, goed voorbeeld doet goed volgen. 
Mijn ouders, lieve papa en mama, dank voor jullie onvoorwaardelijke steun in 
de afgelopen 39 jaar. Jullie hebben de basis gelegd voor degene die ik nu ben; 
ik ben een gelukkig mens. 
David, Mathilde en Julian, jullie zien dingen die de grote mensen niet meer zien, ik
ben blij dat ik daarin mag delen. Ook ik ben benieuwd naar jullie broertje of zusje.
Marco,   love of my life   , zoals je weet ben ik blij met dit proefschrift, maar jouw
humor en scherpe blik betekenen zoveel meer.
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Curriculum Vitae
Hadewych ter Hofstede werd geboren op 16 februari 1969. Na het behalen van
haar VWO diploma (eindexamen in 8 vakken) ging zij in 1987 geneeskunde 
studeren in Nijmegen. In 1995 behaalde zij haar artsdiploma en werkte tot 1997
op de afdeling inwendige geneeskunde in het Rijnstate ziekenhuis in Arnhem. 
In 1997 ging zij werken in het UMC St Radboud in Nijmegen als onderzoeksarts en
als klinisch beoordelaar voor het College ter Beoordeling van Geneesmiddelen. 
In 1998 startte zij haar opleiding tot internist onder leiding van Professor J.W.M.
van der Meer. In 2004 ging zij onder leiding van Professor B.J. Kullberg verder met
haar subspecialisatie infectieziekten. In 2006 rondde zij haar internistenopleiding
af en in 2007 haar subspecialisatie als infectioloog. Zij is thans werkzaam als
internist-infectioloog in het UMC St Radboud en als senior klinisch beoordelaar 
bij het Agentschap College ter Beoordeling van Geneesmiddelen. 
Zij is getrouwd met Marco en samen zorgen zij voor hun kinderen David, 
Mathilde en Julian.
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Alles is anders
Ineens draait alles
en ziet alles er anders uit
verbaasd draai je mee
maar de richting is weg; 
de weg is anders
je volgt
maar begrijpt het niet; 
het uitzicht is anders
je past je aan
aan iets dat er eerst niet was
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1. Het routinematig meten van lactaat is niet aan te bevelen bij mensen die 
antiretrovirale therapie gebruiken. In specifieke gevallen kan het echter 
additionele waarde hebben om bijwerkingen op te sporen. 
2. De huidige morbiditeit en mortaliteit veroorzaakt door HIV is meestal niet
de infectie zelf maar behandeling ervan. 
3. In tegenstelling tot de begindagen van de antiretrovirale combinatietherapie,
zijn lipiden- en glucose-veranderingen nu een van de belangrijkste problemen. 
4. Het meten van geneesmiddelenconcentraties in het bloed (Therapeutic Drug
Monitoring) draagt bij aan het opsporen en vervolgen van bijwerkingen
veroorzaakt door antiretrovirale therapie.
5. De behandeling van HIV-patiënten is continu balanceren tussen goed en 
kwaad doen. 
6. Het ontkennen van HIV-infectie in sommige landen maakt dit gezondheids-
probleem alleen maar groter. 
7. Een organisatie steunt vaak het meest op de mensen die de minste waardering
krijgen.
8. Het snijden in een organisatie in het kader van een bezuinigingsoperatie is 
als het amputeren van een arm en denken dat je afgevallen bent.
9. Als we dit jaar eens geen kerstbomen verlichten, dan verlichten we de 
problemen van de pinguïns. 
10. Life can be understood backwards; but it must be lived forwards. 
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